



6-8-2010

# High-Activity Mutants of Butyrylcholinesterase for Cocaine Hydrolysis and Method of Generating the Same

Chang-Guo Zhan

*University of Kentucky*, zhan@uky.edu

Hoon Cho

*University of Kentucky*

Hsin-Hsiung Tai

*University of Kentucky*, htai1@uky.edu

**Right click to open a feedback form in a new tab to let us know how this document benefits you.**

Follow this and additional works at: [https://uknowledge.uky.edu/ps\\_patents](https://uknowledge.uky.edu/ps_patents)

 Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

## Recommended Citation

Zhan, Chang-Guo; Cho, Hoon; and Tai, Hsin-Hsiung, "High-Activity Mutants of Butyrylcholinesterase for Cocaine Hydrolysis and Method of Generating the Same" (2010). *Pharmaceutical Sciences Faculty Patents*. 49.

[https://uknowledge.uky.edu/ps\\_patents/49](https://uknowledge.uky.edu/ps_patents/49)

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [UKnowledge@lsv.uky.edu](mailto:UKnowledge@lsv.uky.edu).



US007731957B1

(12) **United States Patent**  
**Zhan et al.**

(10) **Patent No.:** **US 7,731,957 B1**  
(45) **Date of Patent:** **Jun. 8, 2010**

(54) **HIGH-ACTIVITY MUTANTS OF BUTYRYLCHOLINESTERASE FOR COCAINE HYDROLYSIS AND METHOD OF GENERATING THE SAME**

(75) Inventors: **Chang-Guo Zhan**, Lexington, KY (US);  
**Hoon Cho**, Lexington, KY (US);  
**Hsin-Hsiung Tai**, Lexington, KY (US)

(73) Assignee: **University of Kentucky Research Foundation**, Lexington, KY (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 130 days.

(21) Appl. No.: **12/192,394**

(22) Filed: **Aug. 15, 2008**

**Related U.S. Application Data**

(62) Division of application No. 11/243,111, filed on Oct. 4, 2005, now Pat. No. 7,438,904.

(51) **Int. Cl.**  
**A61K 38/46** (2006.01)  
**C12N 9/16** (2006.01)

(52) **U.S. Cl.** ..... **424/94.6**; 435/196; 435/197

(58) **Field of Classification Search** ..... 424/94.6;  
435/196, 197

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

7,049,121 B2 5/2006 Watkins et al.  
2003/0153062 A1 8/2003 Watkins et al.  
2004/0120939 A1 6/2004 Watkins et al.

**OTHER PUBLICATIONS**

Gao, et al.; Modeling effects of oxyanion hole on the ester hydrolyses catalyzed by human cholinesterases; *Phys. Chem. B*; 2005; 109; pp. 23070-23076.

Gao, et al; Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition—state simulation; *Angew. Chem. Int. Ed.*; 2006; 45; pp. 653-657.

Gao, et al; Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase; *Proteins*; 2006; 62; pp. 99-110.

Hamza, et al.; Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants; *J. Phys. Chem. B.*; 2005; 109; pp. 4776-4782.

Pan, et al.; Computational redesign of human butyrylcholinesterase for anti-cocaine medication; *G. Proc. Natl. Acad. Sci. USA*; 2005; 102; pp. 16656-16661.

Zhan, et al.; Fundamental reaction mechanism for cocaine metabolism in human butyrylcholinesterase; *J. Am. Chem. Soc.*; 2003; 125; pp. 2462-2474.

Zhan, et al.; Catalytic Mechanism and energy barriers for butyrylcholinesterase—catalyzed hydrolysis of cocaine; *Biophysical Journal*; 2005; 89; pp. 3863-3872.

Xie, et al.; An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4—fold more efficient; *Molecular Pharm.*; 1999; 55; pp. 83-91.

*Primary Examiner*—Tekchand Saidha

(74) *Attorney, Agent, or Firm*—Stites & Harbison PLLC; Mandy Wilson Decker; Stephen Weyer

(57) **ABSTRACT**

A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, and A199S/F227A/S287G/A328W/E441D all have enhanced catalytic efficiency for (–)-cocaine compared with wild-type BChE.

**5 Claims, 6 Drawing Sheets**




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5

(A)




FIGURE 6

**1**

**HIGH-ACTIVITY MUTANTS OF  
BUTYRYLCHOLINESTERASE FOR  
COCAINE HYDROLYSIS AND METHOD OF  
GENERATING THE SAME**

This application is a division of and claims benefit to U.S. patent application Ser. No. 11/243,111, now allowed, filed Oct. 4, 2005 now U.S. Pat. No. 7,438,904. The contents of which are incorporated herein by reference in their entirety.

GOVERNMENT SUPPORT CLAUSE

Subject matter described herein was made with government support under Grant Number R01DA013930 awarded by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). The government has certain rights in the described subject matter.


FIELD OF THE INVENTION

The present invention relates to butyrylcholinesterase variant polypeptides, and in particular, butyrylcholinesterase mutants having amino acid substitutions.


BACKGROUND OF THE INVENTION

Cocaine abuse is a major medical and public health problem that continues to defy treatment. The disastrous medical and social consequences of cocaine addiction, such as violent crime, loss in individual productivity, illness and death, have made the development of an effective pharmacological treatment a high priority. However, cocaine mediates its reinforcing and toxic effects by blocking neurotransmitter reuptake and the classical pharmacodynamic approach has failed to yield small-molecule receptor antagonists due to the difficulties inherent in blocking a blocker. An alternative to receptor-based approaches is to interfere with the delivery of cocaine to its receptors and accelerate its metabolism in the body.

The dominant pathway for cocaine metabolism in primates is butyrylcholinesterase (BChE)-catalyzed hydrolysis at the benzoyl ester group (Scheme 1).



**2**



Scheme 1. Schematic representation of BChE-catalyzed hydrolysis at the benzoyl ester group.

Only 5% of the cocaine is deactivated through oxidation by the liver microsomal cytochrome P450 system. Cocaine hydrolysis at benzoyl ester group yields ecgonine methyl ester, whereas the oxidation produces norcocaine. The metabolite ecgonine methyl ester is a biologically inactive metabolite, whereas the metabolite norcocaine is hepatotoxic and a local anesthetic. BChE is synthesized in the liver and widely distributed in the body, including plasma, brain, and lung. Extensive experimental studies in animals and humans demonstrate that enhancement of BChE activity by administration of exogenous enzyme substantially decreases cocaine half-life.

Enhancement of cocaine metabolism by administration of BChE has been recognized to be a promising pharmacokinetic approach for treatment of cocaine abuse and dependence. However, the catalytic activity of this plasma enzyme is three orders-of-magnitude lower against the naturally occurring (-)-cocaine than that against the biologically inactive (+)-cocaine enantiomer. (+)-cocaine can be cleared from plasma in seconds and prior to partitioning into the central nervous system (CNS), whereas (-)-cocaine has a plasma half-life of approximately 45-90 minutes, long enough for manifestation of the CNS effects which peak in minutes. Hence, BChE mutants with high activity against (-)-cocaine are highly desired for use in humans. Although some BChE mutants with increased catalytic activity over wild-type BChE have previously been generated, there exists a need for

mutant BChE with even higher catalytic activity. Thus, prior mutants provide limited enhancement in catalytic activity over wild-type BChE.

Previous studies such as (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, L. M.; Lockridge, O. *Biochemistry* 1997, 36, 2266 (b) Masson, P.; Xie, W., Froment, M.-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. *Biochim. Biophys. Acta* 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. *Mol. Pharmacol.* 1999, 55, 83, (d) Duyssen, E. G.; Bartels, C. F.; Lockridge, O. *J. Pharmacol. Exp. Ther.* 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. *Eur. J. Biochem.* 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. *J. Phys. Chem. A* 2001, 105, 1296; Berkman, C. E.; Underiner, G. E.; Cashman, J. R. *Biochem. Pharmacol.* 1997, 54, 1261; (g) Sun, H.; Yazal, J. E.; Lockridge, O.; Schopfer, L. M.; Brimijoin, S.; Pang, Y.-P. *J. Biol. Chem.* 2001, 276, 9330, (h) Sun, H.; Shen, M. L.; Pang, Y. P.; Lockridge, O.; Brimijoin, S. *J. Pharmacol. Exp. Ther.* 2002, 302, 710, (i) Sun, H.; Pang, Y. P.; Lockridge, O.; Brimijoin, S. *Mol. Pharmacol.* 2002, 62, 220 (hereinafter "Sun et al"); and (j) Zhan, C.-G.; Zheng, F.; Landry, D. W. *J. Am. Chem. Soc.* 2003, 125, 2462 (hereinafter "Zhan et al"), herein all incorporated by reference, suggested that, for both (-)-cocaine and (+)-cocaine, the BChE-substrate binding involves two different types of complexes: non-prereactive and prereactive BChE-substrate complexes. Whereas the non-prereactive BChE-cocaine complexes were first reported by Sun et al, Zhan et al were the first reporting the prereactive BChE-cocaine complexes and reaction coordinate calculations, disclosed in Zhan et al.

It was demonstrated that (-)/(+)-cocaine first slides down the substrate-binding gorge to bind to W82 and stands vertically in the gorge between D70 and W82 (non-prereactive complex) and then rotates to a position in the catalytic site within a favorable distance for nucleophilic attack and hydrolysis by S198 (prereactive complex). In the prereactive complex, cocaine lies horizontally at the bottom of the gorge. The main structural difference between the BChE(-)-cocaine complexes and the corresponding BChE(+)-cocaine complexes exists in the relative position of the cocaine methyl ester group. Reaction coordinate calculations revealed that the rate-determining step of BChE-catalyzed hydrolysis of (+)-cocaine is the chemical reaction process, whereas for (-)-cocaine the change from the non-prereactive complex to the prereactive complex is rate determining. A further analysis of the structural changes from the non-prereactive complex to the prereactive complex reveals specific amino acid residues hindering the structural changes, providing initial clues for the rational design of BChE mutants with improved catalytic activity for (-)-cocaine.

Previous molecular dynamics (MD) simulations of prereactive BChE-cocaine binding were limited to wild-type BChE. Even for the non-prereactive BChE-cocaine complex, only one mutant (A328W/Y332A) BChE binding with (-)-cocaine was simulated and its catalytic activity for (-)-cocaine was reported by Sun et al. No MD simulation was performed on any prereactive enzyme-substrate complex for (-)- or (+)-cocaine binding with a mutant BChE. In addition, all previous computational studies of Sun et al and Zhan et al of BChE interacting with cocaine were performed based on a homology model of BChE when three-dimensional (3D) X-ray crystal structure was not available for BChE, as taught by Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J. C.; Nachon, F. *J. Biol. Chem.* 2003, 278, 41141 (hereinafter "Nicolet et al"), recently reported 3D X-ray crystal structures of BChE. As expected, the structure of BChE is similar to a

previously published theoretical model of this enzyme and to the structure of acetylcholinesterase.

The main difference between the experimentally determined BChE structure and its model was found at the acyl binding pocket (acyl loop) that is significantly bigger than expected. It is unclear whether the structural difference at the acyl binding pocket significantly affect BChE binding with (-)-cocaine and (+)-cocaine. Although previous MD simulations of cocaine binding with wild-type BChE and the reaction coordinate calculations point to some amino acid residues that might need to be mutated for the purpose of improving the catalytic activity for (-)-cocaine hydrolysis, it remained unknown which exact amino acid mutations will result in a BChE with a higher catalytic activity for (-)-cocaine.

Computational studies of wild-type BChE and cocaine from Sun, et al, based on a "homology model," suggest that the rate-determining step for BChE-catalyzed hydrolysis of cocaine is the rotation of the cocaine in the active site of BChE. By decreasing the hindrance of the rotation, the rate of the hydrolysis may be enhanced. Sun, et al describes creating an A328W/Y332A BChE mutant by: (1) replacing Tyr332 with Ala, "to reduce the steric hindrance and the  $\pi$ - $\pi$  interaction that impede rotation," and (2) replacing Ala328 with Trp "to provide a cation- $\pi$  interaction to restore substrate affinity lost in disabling the  $\pi$ - $\pi$  interaction."

Sun et al studied the A328W/Y332A BChE mutant using enzyme assays and kinetics. In vitro studies were conducted using human plasma and in vivo studies were conducted using male Sprague-Dawley rats. The mutant was found to have enhanced catalytic properties. The mutant was further studied using molecular modeling. The three dimensional (3D) structure of A328W/Y332A was generated from the computationally generated 3D model of wild-type BChE and changing the relevant residues using commercially available software. Cocaine was docked to the catalytic gorge of the mutant BChE using other commercially available software. The cocaine-enzyme complex was refined by molecular dynamic simulation. The data generated by the molecular modeling studies were consistent with enzyme assays and kinetic data.

It should be noted that all prior computational techniques (molecular docking and molecular dynamics simulation) used by other researchers are based on an empirical force field which cannot be used to perform any necessary reaction coordinate calculation for the detailed understanding of the complicated catalytic reaction process. As it is well-known, it is particularly challenging to model and simulate the detailed reaction pathway and predict the kinetics of such an enzymatic reaction.

U.S. Patent Application Publication Nos. 2004/0121970; 2004/0120939; and 2003/0153062, describe 20+BChE mutants, or "variants," from human and other animals, each having from one to six amino acid alterations and increased cocaine hydrolysis activity. For example, mutants include F227A/A328W; F227A/S287G/A328W; A119S/S287G/A328W; A328W/Y332M/S287G/F227A, A199S/F227A/S/287G/A328W and A119S/F227A/S287G/A328W/Y332M. The mutants have varying increases in catalytic activity, up to 100-fold increase relative to wild-type BChE.

There exists a need in the art for determining which proposed mutant BChEs should have ever increasing catalytic activity and for generating those mutants which should have enhanced catalytic activity.

#### SUMMARY OF THE INVENTION

The present invention includes five novel human BChE mutants that have unexpected increased catalytic efficiency for cocaine hydrolysis. The mutants have various unique amino acid residue substitutions which provide the surprising enhanced catalytic activity. These mutants are (1) a 199S/A328W/Y332G mutant (SEQ ID NO: 2), which has an approximately 65-fold improved catalytic efficiency against (-)-cocaine; (2) a 199S/F227A/A328W/Y332G mutant (SEQ ID NO: 8), which has an approximately 148-fold improved catalytic efficiency against (-)-cocaine; (3) a 199S/S287G/A328W/Y332G mutant (SEQ ID NO: 14), which has an approximately 456-fold improved catalytic efficiency against (-)-cocaine; a 199S/F227A/S287G/A328W/Y332G mutant (SEQ ID NO: 20), which has an approximately 1,003-fold improved catalytic efficiency against (-)-cocaine; and a 199S/F227A/S287G/A328W/E441D mutant (SEQ ID NO: 26), which has an approximately 445-fold improved catalytic efficiency against (-)-cocaine.

In addition, the aforementioned mutant amino acid sequences can be truncated without substantially affecting the catalytic activity so that amino acid residues 1-67 and 443-574 can be removed without substantially affecting the catalytic activity of the enzyme. SEQ ID NOS: 4, 10, 16, 22 and 28 are the amino acid sequences for residue 68-142 corresponding to mutants 1-5, respectively. In addition, with regard to mutants 1-4, it was found that amino acid residues before 117 and after 438 could be removed without substantially changing the activity of the mutant enzymes, resulting in truncated amino acid sequences having SEQ ID NOS: 6, 12, 18 and 24, respectively. Finally with regard to mutant 5, amino acid residues before 117 and after 441 could be removed without substantially changing its activity resulting in SEQ ID NO: 30.

These aforementioned truncated sequences all of with similar catalytic activity is based on protein structures.

Further, the present invention is directed to a novel and unique pharmaceutical composition which comprises a butyrylcholinesterase variant, namely mutants 1-5, along with a suitable pharmaceutical carrier. The pharmaceutical composition can be administered to an individual in an effective amount to lower the patient's cocaine blood concentration and in particular (-)-cocaine blood concentration.

In addition, the present invention is directed to a novel and unique method for developing mutants which have enhanced catalytic efficiency. The generation method includes both a computational portion and an experimental portion. With regard to the computational portion, a variety of state of the art computational techniques including molecular modeling, molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations, provide a virtual screening of possible BChE mutants. This virtual screening predicts which mutation will lead to a more stable transition state for a rate-determining step compared to the corresponding separated reactants, i.e., free cocaine and free enzyme. The more stable the transition state, the lower the energy barrier, and the higher the catalytic efficiency. Following the computational portion, an experimental test is then conducted on the possible mutants of the computation portion. The experimental test includes site-directed mutagenesis, protein expression, and enzyme activity assay.

The experimental tests are conducted on mutants which are predicted to have a high catalytic efficiency against (-)-cocaine than the wild-type BChE and/or other known BChE mutants against (-)-cocaine. Thus, the present method identifies or predicts mutants having high catalytic activity for cocaine hydrolysis by performing molecular modeling and MD simulations on the transition state structures of possible mutants of BChE. This method is an improvement over traditional random-search approaches, which, given the complex catalytic mechanism of cocaine hydrolysis, makes it difficult to improve the catalytic activity of BChE for cocaine hydrolysis.

The present invention in one form, concerns a butyrylcholinesterase variant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30.

The present invention in another form thereof concerns a nucleic acid molecule comprising a nucleic acid sequence which encodes a butyrylcholinesterase variant peptide, the nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and 29.

The present invention in another form thereof concerns a pharmaceutical composition comprising a butyrylcholinesterase variant polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable pharmaceutical carrier.

The present invention in another form thereof concerns a method for treating a cocaine-induced condition comprising administering to an individual an effective amount of butyrylcholinesterase variant peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood cocaine concentration.

The present invention is another form thereof concerns a method for treating a cocaine induced condition comprising administering to an individual an effective amount of a pharmaceutical composition comprising a butyrylcholinesterase variant having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier of claim 3 to an individual in an effective amount to lower blood cocaine concentration.

The present invention in yet another form thereof concerns a method for generating butyrylcholinesterase mutants. The method includes generating an initial structure of the transition state structure for the rate-determining step of the cocaine hydrolysis catalyzed by a possible butyrylcholinesterase mutant. A sufficiently long time molecular dynamics simulation is performed on the transition state structure in water to have a stable molecular dynamics trajectory. The molecular dynamics trajectory is analyzed and the hydrogen bonding energies are estimated between the carboxyl oxygen of the (-)-cocaine benzyl ester and the oxyanion hole of the possible butyrylcholinesterase mutant. If the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzyl ester and the possible butyrylcholinesterase mutant, in the transition state, is stronger than the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzyl ester and the wild-type butyrylcholinesterase, optionally, hybrid quantum mechanical/molecular mechanical (QM/MM) geometry optimization is performed to refine the molecular dynamics-simulated structure, the hydrogen binding energies are calculated and the energy barrier is evaluated. Finally, the butyrylcholinesterase mutant is generated.

In various alternative embodiments, the generating an initial structure of the transition state structure is based on reaction coordinate calculations for the wild-type butyrylcholinesterase. The generating butyrylcholinesterase mutant includes performing site-directed mutagenesis on a nucleic acid sequence which includes wild-type butyrylcholinesterase to generate the mutant butyrylcholinesterase nucleic acid sequence. Using the mutant butyrylcholinesterase nucleic acid sequence, the protein encoded by the mutant nucleic acid sequences is expressed to produce mutant butyrylcholinesterase and catalytic activity assay is performed on the mutant butyrylcholinesterase.

The hybrid quantum mechanical/molecular mechanical geometry optimization may include calculating the hydrogen binding energies and evaluating the energy barriers only if the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzyl ester and the possible butyrylcholinesterase mutant, in the transition state, is stronger than known butyrylcholinesterase mutants against (-)-cocaine.

In yet another alternative further embodiment, the method for generating butyrylcholinesterase mutants further includes determining the rate-limiting step in the hydrolysis of (-)-cocaine by the possible butyrylcholinesterase mutant by conducting molecular dynamics simulations and quantum mechanical/molecular mechanical calculations relating to the transition states for other reaction steps between (-)-cocaine by the possible butyrylcholinesterase mutant and calculating respective energy barriers, thereby establishing which of the reaction steps is the rate-determining one.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 are plots of distances in the MD simulation (-)-cocaine binding with A328W/Y332G BChE versus the simulation time, along with root-mean-square deviation (RMSD) in the enzyme-substrate complexes where FIG. 1A represents the non-prereactive enzyme-substrate complexes; and FIG. 1B represents the prereactive enzyme-substrate complexes in accordance with the present invention.

FIG. 2 shows the binding of structures of the simulated non-prereactive and prereactive complexes of wild-type BChE binding with two enantiomers of cocaine in which FIG. 2A depicts BChE (-)-cocaine non-prereactive complex; FIG. 2B depicts BChE (-)-cocaine prereactive complex, FIG. 2C depicts BChE (+)-cocaine non-prereactive complex; and FIG. 2D depicts BChE (+)-cocaine prereactive complex.

FIG. 3A shows the (-)-cocaine rotation in the BChE active site for the non-prereactive complex to the prereactive complex hindered by some residues at positions Y332, A328, and F329 residues in the non-prereactive complexes which are significantly different from the corresponding positions in the prereactive complex; and FIG. 3B shows the (+)-cocaine

rotation in the BChE active site where none of the aforementioned residues hinders the (+)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex in accordance with the present invention.

FIG. 4A depicts the (-)-cocaine rotation in the active site of A328W/Y332A; FIG. 4B depicts the (-)-cocaine rotation in the active site of A328W/Y332G BChE from the non-prereactive complex to the prereactive complex; and FIG. 4C depicts the (-)-cocaine rotation in the active site of wild-type BChE.

FIG. 5A is a plot of the key internuclear distances (in Å) versus the time in the simulated TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A; and FIG. 5B for A199S/A328W/Y332G BChE.

FIG. 6 is a plot of key internuclear distances (in Å) versus the time in the simulated TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention has two major improvements over the prior art. The first is the presently discovered BChE mutants, mutant 1, A199S/A328W/Y332G; mutant 2, A199S/F227A/A328W/Y332G; mutant 3, A199S/S287G/A328W/Y332G; mutant 4, A199S/F227A/S287G/A328W/Y332G; and mutant 5, A199S/F227A/S287G/A328W/E441D each have a significantly higher catalytic efficiency. The second improvement is concerning the mutant designing or discovering process.

The BChE mutants 1-5 have full length amino acid sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively, which are encoded by nucleic acid sequences having SEQ ID NOS: 1, 7, 13, 19, and 25, respectively. Table 1 summarizes the catalytic efficiency against (-)-cocaine for the five mutants.

In addition to the full length BChE mutants, the respective amino acid sequence can be truncated without substantially affecting the respective catalytic activity. With all mutants, residues 1-67 and 443-574 can be removed without substantially affecting the catalytic activity of the respective mutant BChE. Further, with regard to mutant 1-4, amino acids 1-116 and 439-574 can be omitted without substantially affecting its respective catalytic activity. With regard to mutant 5, amino acid residues 1-116 and 442-574 can be omitted without substantially affecting its catalytic activity. Table 1 also provides a summary of amino acid SEQ ID NOS and corresponding nucleic acid SEQ ID NOS for the aforementioned truncated mutant BChE sequences.

TABLE 1

Mutant Number	Amino Acid Substituting	Nucleic Acid SEQ ID NO.	Amino Acid SEQ ID NO.	Partially Truncated Nucleic Acid Sequence Corresponding To Amino Acid Residues 68-442	SEQ ID NO. for Amino Acid Residues 68-442	SEQ ID NO. Corresponding To Amino Acid Residues 117-438/441*	SEQ ID NO. for Amino Acid Residues 117-438/441*	Catalytic Efficiency Against (-)-cocaine
1	A199S/A328W/Y332G	1	2	3	4	5	6	65-fold
2	A199S/F227A	7	8	9	10	11	12	148-fold

TABLE 1-continued

Mutant Number	Amino Acid Substituting	Nucleic Acid SEQ ID NO.	Amino Acid SEQ ID NO.	Partially Truncated Nucleic Acid Sequence Corresponding To Amino Acid Residues 68-442	SEQ ID NO. for Amino Acid Residues 68-442	SEQ ID NO. Corresponding To Amino Acid Residues 117-438/441*	SEQ ID NO. for Amino Acid Residues 117-438/441*	Catalytic Efficiency Against (-)-cocaine
3	A328W/ Y332G A199S/ S287G/	13	14	15	16	17	18	456-fold
4	A328W/ Y332G A199S/ F227A/ S287G/	19	20	21	22	22	24	1,003-fold
5	A328W/ Y332G A199S/ F227A/ S287G/ A328W/ E441D	25	26	27	28	29	30	445-fold

(\*Amino acid residues 117-438 for mutants 1-4 and residues 117-441 for mutant 5.)

The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 can be formulated in a pharmaceutical composition along with a suitable pharmaceutical carrier known to one skilled in the art.

The present BChE variant polypeptides can be used in treating a cocaine-induced condition by administering to an individual, an effective amount of one of the BChE variant polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood cocaine concentration. The BChE variant polypeptide may be administered in the form of a pharmaceutical composition in which the BChE variant is included with a suitable pharmaceutical carrier. Treatment of a cocaine induced condition using one of the aforementioned BChE variant polypeptides can be done in accordance with Zhan et al., page 2463.

The preferred dose for administration of a butyrylcholinesterase or peptide composition in accordance with the present invention is that amount which will be effective in lowering (-)-cocaine concentration in a patient's bloodstream, and one would readily recognize that this amount will vary greatly depending on the nature of cocaine consumed, e.g., injected or inhaled, and the condition of a patient. An "effective amount" of butyrylcholinesterase mutant or pharmaceutical agent to be used in accordance with the invention is intended to mean a nontoxic but sufficient amount of the agent, such that the desired prophylactic or therapeutic effect is produced. Thus, the exact amount of the enzyme or a particular agent that is required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular carrier or adjuvant being used and its mode of administration, and the like. Similarly, the dosing regimen should also be adjusted to suit the individual to whom the composition is administered and will once again vary with age, weight, metabolism, etc. of the individual. Accordingly, the "effective amount" of any particular butyrylcholinesterase composition will vary based on the particular circumstances, and an appropriate effective amount may be determined in each case of application by one of ordinary skill in the art using only routine experimentation.

A unique method was used to determine potential BChE mutants with projected increased catalytic activity for the hydrolysis of cocaine. The method provides a unique

25

30

35

40

45

50

55

60

65

approach which first models the potential BChE mutant interaction with cocaine followed by generating the BChE mutant if the predicted model indicates that the BChE variant should have enhanced catalytic activity. The method includes generating an initial structure of the transition state structure for the rate-determining step for the cocaine hydrolysis catalyzed by a possible BChE mutant. A sufficiently long time molecular dynamics simulation is performed on the transition state structure in water to have a stable molecular dynamics trajectory. The molecular dynamics trajectory is analyzed and the hydrogen binding energies are estimated between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the oxyanion hole of the possible BChE mutant. If the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the possible BChE mutant, in the transition state, is stronger than the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the wild-type BChE, hybrid quantum mechanical/molecular mechanical (QM/MM) geometry optimization is performed to refine the molecular dynamics-simulated structure, the hydrogen binding energies are calculated and the energy barrier is evaluated. The QM/MM calculations make the computational predictions more reliable. Finally, the BChE mutant is generated.

With regard to the molecular dynamics (MD) simulations and quantum mechanical/molecular mechanical (QM/MM) calculations, the first chemical reaction step of (-)-cocaine hydrolysis catalyzed by butyrylcholinesterase (BChE) mutants and, when needed, other reaction steps are modeled and calculated using molecular dynamics simulations and QM/MM calculations. Following this modeling, mutant BChE's are created using site-directed mutagenesis followed by protein expression. The aforementioned five mutants were identified by computational analysis and generated by site-directed mutagenesis which have significantly enhanced (-)-cocaine hydrolysis catalytic efficiency compared with wild-type BChE.

In the present method computational analysis in the form of molecular modeling of a potential BChE mutant and MD simulations and QM/MM calculations provide virtual screening of possible BChE mutants which have predicted enhanced catalytic activity for (-)-cocaine. For example, the MD simulations and QM/MM calculations predict which mutation will lead to a more stable transition state for the rate determining

step compared to the corresponding separated reagents, i.e., free cocaine and free possible mutant BChE, where the more stable transition state leads to a lower energy barrier and higher predicted catalytic efficiency. Only after the computational analysis predicts enhanced catalytic efficiency, is site-directed mutagenesis conducted on wild-type BChE nucleic acid sequence to generate a mutant nucleic acid sequence which is then used to express a mutant BChE protein. The mutant BChE protein is then used in catalytic assays to determine the catalytic efficiency against (-)-cocaine.

The use of predictive, computational modeling of the present method for identifying mutant BChE candidates and the resulting mutant BChE are novel and unexpected over prior conventional methods which will now be readily apparent to one of ordinary skill in the art.

Using the present method, most discovered new mutants include a specific mutation (Y332G) on residue #332. No prior BChE mutant having the Y332G mutation had ever been reported previously; only mutations Y332A and Y332M on residue #332 had been tested previously by other researchers. Prior to the present invention, there was no reason to expect that a mutant including Y332G mutation should be better than the corresponding mutant including Y332A mutation or Y332M. Thus, the present mutants with a Y332G mutation which have enhanced catalytic activity represent a surprising and unexpected result over prior BChE mutants.

A Y332G mutant (single mutation) was first tested and found that the Y332G mutant had a slightly low (or approximately equal) catalytic efficiency than the wild-type. So, only an appropriate combination of different mutations on different residues could make the enzyme more active. As seen below, the prior art did not reveal that any of the particular combinations tested was expected to have an improved catalytic efficiency. The present method is based on the present unique, extensive computational modeling and simulations of the detailed catalytic mechanism for both the wild-type BChE and the mutants.

The primary improvement of the present method over the prior art is that high-performance computational modeling and simulations of the detailed catalytic mechanism are performed, which includes modeling how cocaine binds with BChE and the subsequent structural transformation and chemical reaction process. The prior art only considered the cocaine binding with the enzyme (BChE) and was unable to examine the detailed catalytic reaction process after the BChE-cocaine binding. When molecular modeling was limited to studying the BChE-cocaine binding, one could only design a mutation to improve the BChE-cocaine binding without knowing whether the mutation will also speedup the subsequent chemical reaction process or not.

To overcome the obstacles of prior challenges to using computational techniques such as molecular docking and molecular dynamics simulation previously used by others which were based on an empirical force field which cannot be used to perform necessary reaction coordinate calculations for the catalytic reaction process, a variety of state-of-the-art computational techniques of homology modeling, molecular docking, molecular dynamics, quantum mechanics (QM), and hybrid quantum mechanics/molecular mechanics (QM/MM) were used for the rational design of the BChE mutants. The combined use of these computational techniques, including QM and QM/MM, led to the study of the detailed reaction coordinate of the BChE-catalyzed hydrolysis of cocaine which, for the first time, provided the detailed structures of all transition states and intermediates existing in the reaction process and the corresponding energetics. These extensive computational modeling and simulation studies provided for the rational design of possible BChE mutants that not only can improve the BChE-cocaine binding, but also can speedup the subsequent chemical reaction process. As a result, one can

now quickly discover the BChE mutants with the significantly improved catalytic efficiency.

In addition, to the differences mentioned above, the present molecular modeling of the BChE-cocaine binding also differs from the prior modeling. The molecular modeling in the prior art considered only one binding mode for each BChE-cocaine system, without modeling the possible cocaine rotation in the BChE active site after the binding. The present method considers two different binding modes for each BChE-cocaine system and the structural transformation between them: non-prereactive and prereactive BChE-cocaine complexes. The present modeling provides more detailed information about the BChE-cocaine binding and the subsequent structural transformation.

The present method includes molecular dynamics simulations performed on the cocaine binding with both the wild-type BChE and the mutants whereas prior molecular dynamics simulations were only performed on the cocaine binding with the wild-type BChE. As is shown below in the following experiments, the computational prediction could be completely wrong without directly modeling and simulating cocaine binding with the proposed mutants.

The present invention will now be discussed with regard to the following non-limiting examples in the form of experiments which are provided to enhance understanding of the present invention but in no way limit its scope or applicability.

EXPERIMENT 1: COMPUTATIONAL STUDY OF COCAINE BINDING WITH WILD-TYPE AND MUTANT BChE'S FOR A328W/Y332G, A328W/Y332A, AND A328W/Y332A/Y419S.

A detailed computational study of cocaine binding with wild-type and mutant BChE's starting from the available X-ray crystal structure of wild-type BChE was performed. The simulated mutants include A328W/Y332G, A328W/Y332A, and A328W/Y332A/Y419S, as simple geometric consideration of the binding site suggests that these mutations could be important for changing the (-)-cocaine rotation from the non-prereactive complex to the prereactive complex. Wet experimental tests were conducted on the catalytic activity of these mutants for (-)-cocaine in order to verify the computational predictions. All of the obtained results clearly demonstrate that molecular modeling and MD simulations of cocaine binding with BChE mutants provide a reliable computational approach to the rational design of high-activity mutants of BChE for the (-)-cocaine hydrolysis.

3D model of BChE. The initial coordinates of human BChE used in the computational studies came from the X-ray crystal structure deposited in the Protein Data Bank (pdb code: 1P0P). The missing residues (D2, D3, E255, D378, D379, N455, L530, E531, and M532) in the X-ray crystal structure were built using the automated homology modeling tool Modeler disclosed by Sali, A.; Blundell, T. L. *J. Mol. Biol.* 1990, 212 403, and Sali, A.; Blundell, T. L. *J. Mol. Biol.* 1993, 234, 779, herein incorporated by reference, and InsightII software (Accelrys, Inc.) with the default parameters.

Molecular docking. Molecular docking was performed for each non-prereactive protein-ligand binding complex. The binding site was defined as a sphere with an approximately 15 Å radius around the active site residue S198. The amino acid residues included in the binding site model are not contiguous in the protein. Cocaine, considered as a ligand, was initially positioned at 17 Å in front of S198 of the binding site. Each BChE-cocaine binding complex was energy-minimized by using the steepest descent algorithm first until the maximum energy derivative is smaller than 4 kcal/mol/Å and then the conjugated gradient algorithm until the maximum energy derivative is smaller than 0.001 kcal/mol/Å. The energy minimization was followed by a 300 ps molecular dynamics (MD) simulation at T=298 K with a time step of 1 fs. During the energy minimization and MD simulation, only cocaine and

the residues of BChE included in the binding site were allowed to move, while the remaining part of the protein was fixed. The energy-minimization and MD simulation for these processes were performed by using the Amber force field implemented in the Discover\_3/InsightII calculation engine, disclosed by Cornell, W. D.; Cieplak, P.; Bayl, C. I.; Gould, I. R.; Merz, Jr., K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. *J. Am. Chem. Soc.* 1995, 117, 5179. The non-bonded cut-off method and the dielectric constant were set up to group based (12 Å cut-off distance) and distance dependent, respectively ( $\epsilon=4r$ ) in accordance with Harvey, S. C. *Proteins* 1989, 5, 78-92, herein incorporated by reference.

Molecular dynamic simulation in water. The initial coordinates used in the MD simulation of the non-prereactive complexes were determined by using the molecular docking procedure described above, whereas the initial coordinates used in the MD simulation of the prereactive complexes were obtained from superimposing backbone of the X-ray crystal structure to that of the previously disclosed simulated prereactive complex of Zhan et al between cocaine and a homology model of wild-type BChE. Each BChE-cocaine binding complex was neutralized by adding two chloride counterions and was solvated in a rectangular box of TIP3P water molecules with a minimum solute-wall distance of 10 Å. The general procedure for carrying out the MD simulations in water is similar to that used in our previously reported other computational studies such as those in Zhan et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rittenhouse, R.; Ornstein, R. L. *J. Am. Chem. Soc.* 1999, 121, 7279, (b) Koca, J.; Zhan, C.-G.; Rittenhouse, R.; Ornstein, R. L. *J. Am. Chem. Soc.* 2001, 123, 817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, R. L. *J. Comput. Chem.* 2003, 24, 368, herein all incorporated by reference. These simulations were performed by using the Sander module of Amber7 program as taught by Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham III, T. E.; Wang, J.; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. (2002), AMBER 7, University of California, San Francisco, herein incorporated by reference. The solvated system was optimized prior to the MD simulation. First, the protein-ligand was frozen and the solvent molecules with counterions were allowed to move during a 5000-step minimization with the conjugate gradient algorithm and a 5 ps MD run at T=300 K. After full relaxation and the entire solvated system was energy-minimized, the system was slowly heated from T=10 K to T=300 K in 30 ps before the production MD simulation for 500 ps. The full minimization and equilibration procedure was repeated for each mutant. The MD simulations were performed with a periodic boundary condition in the NPT ensemble at T=300 K with Berendsen temperature coupling and constant pressure (P=1 atm) with isotropic molecule-based scaling disclosed in Berendsen, H. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. *J. Comp. Phys.* 1984, 81, 3684, herein incorporated by reference. The SHAKE algorithm of Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. C. *J. Comp. Phys.* 1977, 23, 327 (herein incorporated by reference) was applied to fix all covalent bonds containing a hydrogen atom, a time step of 2 fs was used, and the non-bond pair list was updated every 10 steps. The pressure was adjusted by isotropic position scaling. The particle mesh Ewald (PME) method of Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen; L. G. *J. Chem. Phys.* 1995, 98, 10089, herein incorporated by reference, was used to treat long-range electrostatic interactions. A residue-based cutoff of 10 Å was applied to the noncovalent interactions. During the 500 ps production MD simulation, the coordinates of the simulated complex were saved every 1 ps.

Molecular docking and MD simulation procedures described above were performed to study cocaine binding with wild-type BChE and three mutants, i.e., A328W/Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For each protein system (wild-type or mutant BChE), the protein binding with cocaine was considered in both the non-prereactive and prereactive enzyme-substrate complexes.

Most of the MD simulations in water were performed on a supercomputer, Superdome (shared-memory, with 4 nodes and 256 processors), at the Center for Computational Sciences, University of Kentucky. The other computations were carried out on SGI Fuel workstations and a 34-processors IBM x335 Linux cluster.

Experimental procedure. Site-directed mutagenesis of human BChE cDNA was performed by the QuikChange method of Braman, J.; Papworth, C.; Greener, A. *Methods Mol. Biol.* 1996, 57, 5731, herein incorporated by reference. Mutations were generated from wild-type human BChE in a pRc/CMV expression plasmid in accordance with Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. *Mol. Pharmacol.* 1999, 55, 83, all herein incorporated by reference, kindly provided by Dr. Lockridge at University of Nebraska Medical Center. Using plasmid DNA as template and primers with specific base-pair alterations, mutations were made by polymerase chain reaction with Pfu DNA polymerase, for replication fidelity. The PCR product was treated with Dpn I endonuclease to digest the parental DNA template. Modified plasmid DNA was transformed into *Escherichia coli*, amplified, and purified. The DNA sequences of the mutants were confirmed by DNA sequencing. BChE mutants were expressed in human embryonic kidney cell line 293T/17. Cells were grown to 80-90% confluence in 6-well dishes and then transfected by Lipofectamine 2000 complexes of 4 µg plasmid DNA per each well. Cells were incubated at 37° C. in a CO<sub>2</sub> incubator for 24 hours and cells were moved to 60-mm culture vessel and cultured for four more days. The culture medium [10% fetal bovine serum in Dulbecco's modified Eagle's medium (DMEM)] was harvested for a BChE activity assay. To measure cocaine and benzoic acid, the product of cocaine hydrolysis by BChE, we used sensitive radiometric assays based on toluene extraction of [<sup>3</sup>H]cocaine labeled on its benzene ring were used in accordance with Masson, P.; Xie, W.; Froment, M.-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. *Biochim. Biophys. Acta* 1999, 1433, 281, herein incorporated by reference. In brief, to initiate reactions, 100 nCi of [<sup>3</sup>H]cocaine was mixed with 100 µl of culture medium. Reactions proceeded at 37° C. for varying times. Reactions were stopped by adding 300 µl of 0.02 M HCl, which neutralized the liberated benzoic acid while ensuring a positive charge on the residual cocaine. [<sup>3</sup>H]benzoic acid was extracted by 1 ml of toluene and measured by scintillation counting. Finally, the measured time-dependent radiometric data were fitted to the kinetic equation so that the catalytic efficiency ( $k_{cat}/K_M$ ) was determined.

Depicted in FIG. 1 are plots of some important distances in the MD-simulated (–)cocaine binding with A328W/Y332G BChE versus the simulation time, along with root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the simulated structure from those in the X-ray crystal structure. MD trajectories for other complexes were similar to these two in FIG. 1, although the simulated average distances are different. Summarized in Table 2 are the average values of some important geometric parameters in the simulated complexes.

TABLE 2

BChE-cocaine binding <sup>a</sup>	Average values of the geometric parameters <sup>c</sup>						RMSD <sup>d</sup>	
	<D1> <sub>non</sub>	<D1>	<D2>	<D3>	<D4>	<T>	nonpre	re
wild-type	5.60	.27	.77	.71	.37	67	1.14	.27
wild-type with (+)-cocaine <sup>b</sup>	7.64	.69	.88	.30	.83	61	1.15	.13
A328W/Y332A	7.11	.87	.30	.14	.01	51	1.58	1.65
A328W/Y332G	7.06	.96	.28	.52	.42	60	1.20	.35
A328W/Y332A/Y419S	5.18	.84	.64	.56	.97	64	2.66	.62


<sup>a</sup>Refers to (-)-cocaine binding with wild-type human BChE or (-)-cocaine binding with a mutant BChE, unless indicated otherwise.

<sup>b</sup>Refers to (+)-cocaine binding with wild-type human BChE.

<sup>c</sup><D1><sub>non</sub> and <D1> represent the average distances between the S198 O<sup>γ</sup> atom and the carbonyl carbon of the cocaine benzoyl ester in the simulated non-prereactive and prereactive BChE-cocaine complexes, respectively. <D2>, <D3>, <D4> refer to the average values of the simulated distances from the carbonyl oxygen of the cocaine benzoyl ester to the NH hydrogen atoms of G116, G117, and A199 residues, respectively. <T> is the average value of the dihedral angle formed by the S198 O<sup>γ</sup> atom and the plane of the carboxylate group of the cocaine benzoyl ester. See Scheme 2.

<sup>d</sup>The root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the simulated structure from those in the X-ray crystal structure of BChE. "nonpre" and "pre" refer to the non-prereactive and prereactive BChE-cocaine complexes, respectively.

(-)- and (+)-cocaine binding with wild-type BChE. FIG. 2 shows the binding structures of the simulated non-prereactive and prereactive complexes of wild-type BChE binding with the two enantiomers of cocaine. In the non-prereactive complexes with (-)- and (+)-cocaine, the methyl ester group of cocaine is positioned at the top of the H438 backbone, while the cocaine benzoyl ester moiety is quasi-parallel to the C—O<sup>γ</sup> side chain of S198 with a dihedral angle  $\theta$  of  $-8^\circ$  and  $140^\circ$ , respectively.



Scheme 2. Hydrolysis of (-)-cocaine and (+)-cocaine.

Here,  $\theta$  refers to the dihedral angle formed by S198 O<sup>γ</sup> and the plane of carboxylate group of the cocaine benzoyl ester as shown in the structure diagram below.

The simulated internuclear distances between the carbonyl oxygen of cocaine benzoyl ester group and the NH hydrogen of G116, G117, and A199 are comparable for the two enantiomers. The simulated average distances between the carbonyl carbon of the benzoyl ester and S198 O<sup>γ</sup> are 5.60 Å and 5.18 Å for (-)- and (+)-cocaine, respectively. Comparing the simulated protein backbone structures to the X-ray crystal

structure of Nicolet et al, one can see from FIG. 1 that the RMSD values are all smaller than 1.3 Å for the whole protein structures.

The MD simulations of the prereactive complexes reveal that wild-type BChE binding with (-)-cocaine is essentially the same as the binding with (+)-cocaine in the binding site, except for the different positions of methyl ester group of the substrates. The simulated average distances between the carbonyl carbon of the benzoyl ester and S198 O<sup>γ</sup> are 3.27 and 3.69 Å for (-)-cocaine and (+)-cocaine, respectively. Moreover, the (+)-cocaine is stabilized more effectively by the formation of strong hydrogen bonds with the backbone NH of residues G116, G117, and A199 as summarized above in Table 2. The cocaine benzoyl ester moiety is positioned quasi-perpendicular to S198 C—O<sup>γ</sup> with a dihedral angle  $\theta$  of  $-67^\circ$  and  $\sim 61^\circ$  for (-)- and (+)-cocaine, respectively.

A comparison was made between the currently simulated structures of the BChE-cocaine binding with those simulated previously by using a homology model of BChE and it was noted that two major differences between the two sets of structures. By using the X-ray crystal structure in accordance with Nicolet et al, the acyl loop is positioned on the top of the cocaine benzoyl ester moiety of the cocaine, whereas the acyl loop is far from the cocaine benzoyl ester moiety in the structure simulated starting from the homology model of Zhan et al. The RMSD of the coordinates of backbone atoms in the previously simulated prereactive BChE(-)-cocaine complex from those in the X-ray crystal structure of BChE is  $\sim 2.0$  Å for the entire protein and  $\sim 3.0$  Å for the acyl loop. The RMSD value became  $\sim 2.4$  Å for the entire protein and  $\sim 3.3$  Å for the acyl loop, when the X-ray crystal structure was replaced by the MD-simulated prereactive BChE(-)-cocaine complex starting from the X-ray crystal structure. Despite these structural differences, the benzoyl ester group of the ligand is still close to the key residues (S197, G116, and G117) in the BChE binding site. Some significant differences are associated with the distances between the S198 O<sup>γ</sup> atom and the carbonyl carbon of the cocaine benzoyl ester in non-prereactive complexes. The average values of this distance in the non-prereactive complexes were  $\sim 9.5$  and  $\sim 8.5$  Å for (-)- and (+)-cocaine, respectively, when a homology model was used. Using the X-ray crystal structure to conduct the analysis, corresponding average values became  $\sim 5.6$  and  $\sim 5.2$  Å,

respectively. Therefore, both (-) and (+)-cocaine became closer to the binding site when the homology model was replaced by the X-ray crystal structure. However, no significant changes of the binding in the prereactive complexes were observed when the used homology model was replaced by the X-ray crystal structure. The average values of the simulated distance between the S198 O<sup>γ</sup> atom and the carbonyl carbon of the cocaine benzoyl ester in the prereactive complexes are always close to ~3.5 Å for both (-) and (+)-cocaine no matter whether the X-ray crystal structure or homology model of BChE was used as the starting structure. The similar computational results obtained from the use of the X-ray crystal structure and homology model of BChE provides evidence that the fundamental structural and mechanistic insights obtained from the previous computational studies of Zhan et al are reliable, despite the previous simulations were performed by using the homology model when the X-ray crystal structure was not available.

Further, the simulated structures of the non-prereactive BChE-cocaine complexes were superimposed with the corresponding prereactive complexes. As shown in FIG. 3, the (-)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex is hindered by some residues as the positions of Y332, A328, and F329 residues in the non-prereactive complex are significantly different from the corresponding positions in the prereactive complex, whereas none of these residues hinders the (+)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex because these residues stay in nearly the same positions in the two BChE-(+)-cocaine complexes.

(-)-cocaine binding with BChE mutants. Now that the (-)-cocaine rotation from the non-prereactive complex to the prereactive complex has been known to be the rate-determining step of the BChE-catalyzed hydrolysis of (-)-cocaine as shown by Zhan et al, useful BChE mutants should be designed to specifically accelerate the change from the non-prereactive BChE-(-)-cocaine complex to the prereactive complex. The question is whether MD simulation can be performed to help design BChE mutants that have higher catalytic activity for (-)-cocaine hydrolysis.

In the simulated non-prereactive complex, the average distance between the carbonyl carbon of cocaine benzoyl ester and S198 O<sup>γ</sup> is 7.6 Å for A328W/Y332A BChE and 7.1 Å for A328W/Y332G BChE, as seen in Table 2 above. In the simulated prereactive complex, the average values of this important internuclear distance become 3.87 and 3.96 Å for A328W/Y332A and A328W/Y332G BChE's, respectively. Compared to the simulated wild-type BChE-(-)-cocaine prereactive complex, the average distances between the carbonyl carbon of the cocaine benzoyl ester and S198 O<sup>γ</sup> in the prereactive complex of (-)-cocaine with A328W/Y332A and A328W/Y332G BChE's are all slightly longer, whereas the average distances between the carbonyl oxygen of the cocaine benzoyl ester and the NH of G116, G117, and A199 residues are all shorter. This provides evidence that (-)-cocaine more strongly bind with A328W/Y332A and A328W/Y332G BChE's in the prereactive complexes. More importantly, the (-)-cocaine rotation in the active site of A328W/Y332A and A328W/Y332G BChE's from the non-prereactive complex to the prereactive complex did not cause considerable changes of the positions of A332 (or G332), W328, and F329 residues as seen in FIG. 4, compared to the (-)-cocaine rotation in the active site of wild-type BChE. These results provide evidence that A328W/Y332A and A328W/Y332G BChE's should be associated with lower energy barriers than the wild-type for the (-)-cocaine rotation

from the non-prereactive complex to the prereactive complex. Further, (-)-cocaine binding with A328W/Y332G BChE is very similar to the binding with A328W/Y332A BChE, but the position change of F329 residue caused by the (-)-cocaine rotation was significant only in A328W/Y332A BChE, thus suggesting that the energy barrier for the (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE.

Concerning (-)-cocaine binding with A328W/Y332A/Y419S BChE, Y419 stays deep inside the protein and does not directly contact with the cocaine molecule. The Y419S mutation was tested because it was initially expected that this mutation would further increase the free space of the active site pocket so that the (-)-cocaine rotation could be easier. However, as seen in Table 2 above, the average distance between the carbonyl carbon of cocaine benzoyl ester and S198 O<sup>γ</sup> atom in the simulated prereactive complex was as long as 5.84 Å. The average distances between the carbonyl oxygen of the cocaine benzoyl ester and the NH hydrolysis atoms of G116, G117, and A199 residues are between 4.56 and 6.97 Å; no any hydrogen bond between them. In addition to the internuclear distances, another interesting geometric parameter is the dihedral angle,  $\theta$ , formed by S198 O<sup>γ</sup> and the plane of the carboxylate group of the cocaine benzoyl ester. As seen in Table 2, the  $\theta$  values in the prereactive complexes of cocaine with wild-type BChE and all of the BChE mutants other than A328W/Y332A/Y419S BChE all slightly deviate from the ideal value of 90° for the nucleophilic attack of S198 O<sup>γ</sup> at the carbonyl carbon of cocaine. The  $\theta$  value in the prereactive complex of (-)-cocaine with A328W/Y332A/Y419S BChE is 164°, which is considerably different from the ideal value of 90°.

Catalytic activity. The aforementioned discussion provides evidence that the energy barriers for the (-)-cocaine rotation in A328W/Y332A and A328W/Y332G BChE's from the non-prereactive complex to the prereactive complex, the rate-determining step for the BChE-catalyzed hydrolysis of (-)-cocaine, should be lower than that in the wild-type BChE. Thus, the MD simulations predict that both A328W/Y332A and A328W/Y332G BChE's should have a higher catalytic activity than the wild-type BChE for (-)-cocaine hydrolysis. Further, the MD simulations also suggest that the energy barrier for the (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE and, therefore, the catalytic activity of A328W/Y332G BChE for the (-)-cocaine hydrolysis should be slightly higher than the activity of A328W/Y332A BChE. In addition, the MD simulations predict that A328W/Y332A/Y419S BChE should have no catalytic activity, or have a considerably lower catalytic activity than the wild-type, for (-)-cocaine hydrolysis because (-)-cocaine binds with the mutant BChE in a way that is not suitable for the catalysis.

The catalytic efficiency ( $k_{cat}/K_M$ ) of A328W/Y332A BChE for (-)-cocaine hydrolysis was reported to be  $8.56 \times 10^6 \text{ min}^{-1}$ , which is 9.39 times of the  $k_{cat}/K_M$  value ( $9.11 \times 10^5 \text{ min}^{-1}$ ) of the wild-type BChE. To examine these theoretical predictions of the relative activity for A328W/Y332G and A328W/Y332A/Y419S BChE's, a A328W/Y332A, A328W/Y332G, and A328W/Y332A/Y419S BChE was produced through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with all of three mutants under the same condition and compared the catalytic efficiency of the A328W/Y332G and A328W/Y332A/Y419S to that of the A328W/Y332A for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data, the ratio of the  $k_{cat}/$

19

$K_M$  value of A328W/Y332G BChE to the  $k_{cat}/K_M$  value of A328W/Y332A BChE for the (-)-cocaine hydrolysis was determined to be  $\sim 2.08$ , or A328W/Y332G BChE has a  $k_{cat}/K_M$  value of  $\sim 1.78 \times 10^7 \text{ M}^{-1} \text{ min}^{-1}$  for the (-)-cocaine hydrolysis. The radiometric data show no significant catalytic activity for A328W/Y332A/Y419S BChE. These experimental data are consistent with the theoretical predictions based on the MD simulations.

Conclusion. Molecular modeling, molecular docking, and molecular dynamics (MD) simulations were performed to study cocaine binding with human butyrylcholinesterase (BChE) and its mutants, based on a recently reported X-ray crystal structure of human BChE. The MD simulations of cocaine binding with wild-type BChE led to average BChE-cocaine binding structures similar to those obtained recently from the MD simulations based on a homology model of BChE, despite the significant difference found at the acyl binding pocket. This confirms the fundamental structural and mechanistic insights obtained from the prior computational studies of Zhan et al based on a homology model of BChE, e.g., the rate-determining step for BChE-catalyzed hydrolysis of biologically active (-)-cocaine is the (-)-cocaine rotation in the BChE active site from the non-prereactive BChE-(-)-cocaine complex to the prereactive complex.

The MD simulations further reveal that the (-)-cocaine rotation in the active site of wild-type BChE from the non-prereactive complex to the prereactive complex is hindered by some residues such that the positions of Y332, A328, and F329 residues in the non-prereactive complex are significantly different from those in the prereactive complex. Compared to (-)-cocaine binding with wild-type BChE, (-)-cocaine more strongly bind with A328W/Y332A and A328W/Y332G BChE's in the prereactive complexes. More importantly, the (-)-cocaine rotation in the active site of A328W/Y332A and A328W/Y332G BChE's from the non-prereactive complex to the prereactive complex did not cause considerable changes of the positions of A332 or G332, W328, and F329 residues. These results provide evidence that A328W/Y332A and A328W/Y332G BChE's are associated with lower energy barriers than wild-type BChE for the (-)-cocaine rotation from the non-prereactive complex to the

20

prereactive complex. Further, (-)-cocaine binding with A328W/Y332G BChE is very similar to the binding with A328W/Y332A BChE, but the position change of F329 residue caused by the (-)-cocaine rotation was significant only in A328W/Y332A BChE, thus suggesting that the energy barrier for (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE. It has also been demonstrated that (-)-cocaine binds with A328W/Y332A/Y419S BChE in a way that is not suitable for the catalysis.



Based on the computational results, both A328W/Y332A and A328W/Y332G BChE's have catalytic activity for (-)-cocaine hydrolysis higher than that of wild-type BChE and the activity of A328W/Y332G BChE should be slightly higher than that of A328W/Y332A BChE, whereas A328W/Y332A/Y419S BChE is expected to lose the catalytic activity. The computational predictions are completely consistent with the experimental kinetic data, providing evidence that the used computational protocol, including molecular modeling, molecular docking, and MD simulations, is reliable in prediction of the catalytic activity of BChE mutants for (-)-cocaine hydrolysis.


EXPERIMENT 2: MD SIMULATIONS AND QUANTUM MECHANICAL/MOLECULAR MECHANICAL (QM/MM) CALCULATIONS RELATING TO A 199S/A328W/Y332G MUTANT (MUTANT 1) (SEQ ID NO: 1).

Generally speaking, for rational design of a mutant enzyme with a higher catalytic activity for a given substrate, one needs to design a mutation that can accelerate the rate-determining step of the entire catalytic reaction process while the other steps are not slowed down by the mutation. Reported computational modeling and experimental data indicated that the formation of the prereactive BChE-(-)-cocaine complex (ES) is the rate-determining step of (-)-cocaine hydrolysis catalyzed by wild-type BChE as disclosed by Sun et al, Zhan et al and Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. *J. Phys. Chem. B* 2005, 109, 4776, herein incorporated by reference, whereas the rate-determining step of the corresponding (+)-cocaine hydrolysis is the chemical reaction process consisting of four individual reaction steps disclosed by Zhan et al and shown in Scheme 3 and Scheme 4 below.

21

22





Scheme 3. Schematic representation of BChE-catalyzed hydrolysis of (-)-cocaine. Only QM-treated high-layer part of the reaction system in the QM/MM calculations are drawn. Notation [H] refers to a non-hydrogen atom in the MM-treated low-layer part of the protein and the cut covalent bond with this atom is saturated by a hydrogen atom. The dash lines in the transition state structures represent the transition bonds.

This mechanistic understanding is consistent with the experimental observation of Sun et al, that the catalytic rate constant of wild-type BChE against (+)-cocaine is pH-dependent, whereas that of the same enzyme against (-)-cocaine is independent of the pH. The pH-dependence of the rate constant for (+)-cocaine hydrolysis is clearly associated with the protonation of H438 residue in the catalytic triad (S198, H438, and E325). For the first and third steps of the reaction process, when H438 is protonated, the catalytic triad cannot function and, therefore, the enzyme becomes inactive. The lower the pH of the reaction solution is, the higher the concentration of the protonated H438 is, and the lower the concentration of the active enzyme is. Hence, the rate constant was found to decrease with decreasing the pH of the reaction solution for the enzymatic hydrolysis of (+)-cocaine.

Based on the above mechanistic understanding, the efforts for rational design of the BChE mutants reported in literature have been focused on how to improve the ES formation process. Indeed, several BChE mutants, including A328W, A328W/Y332A, A328W/Y332G, and F227A/S287G/A328W/Y332M, have been found to have a significantly higher catalytic efficiency ( $k_{cat}/K_M$ ) against (-)-cocaine; these mutants of BChE have an approximate 9 to 34-fold improved catalytic efficiency against (-)-cocaine. Experimental observation also indicated that the catalytic rate constant of A328W/Y332A BChE is pH-dependent for both (-)- and (+)-cocaine. The pH-dependence reveals that for both (-)- and (+)-cocaine, the rate-determining step of the hydrolysis catalyzed by A328W/Y332A BChE should be either the first or the third step of the reaction process. Further, if the third step were rate determining, then the catalytic efficiency of the A328W/Y332A mutant against (-)-cocaine should be as high as that of the same mutant against (+)-cocaine because the (-)- and (+)-cocaine hydrolyses share the same third and fourth steps (see Scheme 3). However, it has also been observed that the A328W/Y332A mutant only has a ~9-fold improved catalytic efficiency against (-)-cocaine, whereas the A328W/Y332A mutation does not change the high catalytic activity against (+)-cocaine. This analysis of the experimental and computational data available in literature clearly shows that the rate-determining step of (-)-cocaine hydrolysis catalyzed by the A328W/Y332A mutant should be the first step of the chemical reaction process. Further, recently reported computational modeling also suggests that the formation of the prereactive BChE-(-)-cocaine complex (ES) is hindered mainly by the bulky side chain of Y332 residue in wild-type BChE, but the hindering can be removed by the Y332A or Y332G mutation. Therefore, starting from the A328W/Y332A or A328W/Y332G mutant, the truly rational design of further mutation(s) to improve the catalytic efficiency of BChE against (-)-cocaine should aim to decrease the energy barrier for the first reaction step without significantly affecting the ES formation and other chemical reaction steps.

The following rational design of a high-activity mutant of BChE against (-)-cocaine is based on detailed computational modeling of the transition state for the rate-determining step (i.e., the first step of the chemical reaction process). Molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations

were performed to model the protein environmental effects on the stabilization of the transition-state structure for BChE-catalyzed hydrolysis of (-)-cocaine. The simulated and calculated results indicate that the transition-state structure can be stabilized better by the protein environment in A199S/A328W/Y332G mutant of BChE than that in the wild-type. The computational modeling led to a prediction of the higher catalytic efficiency for the A199S/A328W/Y332G mutant against (-)-cocaine. The prediction has been confirmed by wet experimental tests showing that the A199S/A328W/Y332G mutant has a significantly improved catalytic efficiency against (-)-cocaine. All of the obtained results clearly demonstrate that directly modeling the transition-state structure provides a reliable computational approach to the rational design of a high-activity mutant of BChE against (-)-cocaine.

MD simulations. It should be stressed that a critical issue exists with regard to any MD simulation on a transition state. In principle, MD simulation using a classical force field (molecular mechanics) can only simulate a stable structure corresponding to a local minimum on the potential energy surface, whereas a transition state during a reaction process is always associated with a first-order saddle point on the potential energy surface. Hence, MD simulation using a classical force field cannot directly simulate a transition state without any restraint on the geometry of the transition state. Nevertheless, if one can technically remove the freedom of imaginary vibration in the transition state structure, then the number of vibrational freedoms (normal vibration modes) for a nonlinear molecule will decrease from  $3N-6$ . The transition state structure is associated with a local minimum on the potential energy surface within a subspace of the reduced vibrational freedoms, although it is associated with a first-order saddle point on the potential energy surface with all of the  $3N-6$  vibrational freedoms. Theoretically, the vibrational freedom associated with the imaginary vibrational frequency in the transition state structure can be removed by appropriately freezing the reaction coordinate. The reaction coordinate corresponding to the imaginary vibration of the transition state is generally characterized by a combination of some key geometric parameters. These key geometric parameters are bond lengths of the forming and breaking covalent bonds for BChE-catalyzed hydrolysis of cocaine, as seen in Scheme 3. Thus, one just needs to maintain the bond lengths of the forming and breaking covalent bonds during the MD simulation on a transition state. Technically, one can maintain the bond lengths of the forming and breaking covalent bonds by simply fixing all atoms within the reaction center, by using some constraints on the forming and breaking covalent bonds, or by redefining the forming and breaking covalent bonds. It should be pointed out that the only purpose of performing such type of MD simulation on a transition state is to examine the dynamic change of the protein environment surrounding the reaction center and the interaction between the reaction center and the protein environment. For this study, of interest is the simulated structures, as the total energies calculated in this way are meaningless.

The initial BChE structures used in the MD simulations were prepared based on the previous MD simulation in accordance with Hamza et al on the prereactive ES complex for wild-type BChE with (-)-cocaine in water by using Amber7 program package. The previous MD simulations on the prereactive BChE-(-)-cocaine complex (ES) started from the X-ray crystal structure of Nicolet et al deposited in the Protein Data Bank (pdb code: 1POP). The present MD simulation on the transition state for the first step (TS1) was performed in such a way that bond lengths of the partially formed and

partially broken covalent bonds in the transition state were all constrained to be the same as those obtained from our previous ab initio reaction coordinate calculations on the model reaction system of wild-type BChE in accordance with Zhan et al. The partially formed and partially broken covalent bonds in the transition state will be called "transition" bonds below, for convenience. A sufficiently long MD simulation with the transition bonds constrained should lead to a reasonable protein environment stabilizing the reaction center in the transition-state structure simulated. Further, the simulated TS1 structure for wild-type BChE with (-)-cocaine was used to build the initial structures of TS1 for the examined BChE mutants with (-)-cocaine; only the side chains of mutated residues needed to be changed.

The partial atomic charges for the non-standard residue atoms, including cocaine atoms, in the TS1 structures were calculated by using the RESP protocol implemented in the Antechamber module of the Amber7 package following electrostatic potential (ESP) calculations at ab initio HF/6-31G\* level using Gaussian03 program known in the art. The geometries used in the ESP calculations came from those obtained from the previous ab initio reaction coordinate calculations of Zhan et al, but the functional groups representing the oxyanion hole were removed. Thus, residues G116, G117, and A199 were the standard residues as supplied by Amber7 in the MD simulations. The general procedure for carrying out the MD simulations in water is essentially the same as that used in our previously reported other computational studies including Zhan et al, Hamza et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rittenhouse, R.; Ornstein, R. L. *J. Am. Chem. Soc.* 1999, 121, 7279, (b) Koca, J.; Zhan, C.-G.; Rittenhouse, R.; Ornstein, R. L. *J. Am. Chem. Soc.* 2001, 123, 817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, R. L. *J. Comput. Chem.* 2003, 24, 368, (d) Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. *Bioorg. Med. Chem.* 2005, 13, 4544, herein all incorporated by reference. Each aforementioned starting TS1 structure was neutralized by adding chloride counterions and was solvated in a rectangular box of TIP3P water molecules with a minimum solute-wall distance of 10 Å as described by Jorgensen, W. L.; Chandrasekhar, J.; Madura, J.; Klein, M. L. *J. Chem. Phys.* 1983, 79, 926, herein incorporated by reference. The total numbers of atoms in the solvated protein structures for the MD simulations are nearly 70,000, although the total number of atoms of BChE and (-)-cocaine is only 8417 (for the wild-type BChE). All of the MD simulations were performed by using the Sander module of Amber7 package. The solvated systems were carefully equilibrated and fully energy minimized. These systems were gradually heated from T=10 K to T=298.15 K in 30 ps before running the MD simulation at T=298.15 K for 1 ns or longer, making sure that a stable MD trajectory was obtained for each of the simulated TS1 structures. The time step used for the MD simulations was 2 fs. Periodic boundary conditions in the NPT ensemble at T=298.15 K with Berendsen temperature coupling and P=1 atm with isotropic molecule-based scaling were applied. The SHAKE algorithm was used to fix all covalent bonds containing hydrogen atoms. The non-bonded pair list was updated every 10 steps. The particle mesh Ewald (PME) method in accordance with Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen, L. G. *J. Chem. Phys.* 1995, 98, 10089, herein incorporated by reference, was used to treat long-range electrostatic interactions. A




residue-based cutoff of 10 Å was utilized to the non-covalent interactions. The coordinates of the simulated systems were collected every 1 ps during the production MD stages.

QM/MM calculations. For each TS1 structure examined, after the MD simulation was completed and a stable MD trajectory was obtained, all of the collected snapshots of the simulated structure, excluding those before the trajectory was stabilized, were averaged and further energy-minimized. The energy-minimized average structure (with the transition bonds constrained) was used as an initial geometry to carry out a further geometry optimization by using the ONIOM approach of Dapprich, S.; Komaromi, I.; Byun, K. S.; Morokuma, K.; Frisch, M. J. *J. Mol. Struct. (Theochem)* 1999, 461, 1-21, herein incorporated by reference, implemented in the Gaussian03 program of Frisch, M. J. et al *Gaussian 03*, Revision A.1, Gaussian, Inc., Pittsburgh, Pa., 2003, herein incorporated by reference. Two layers were defined in the present ONIOM calculation: the high layer, as depicted in Scheme 3 above, was calculated quantum mechanically at the ab initio HF/3-21G level, whereas the low layer was calculated molecular mechanically by using the Amber force field as used in our MD simulation and energy minimization with the Amber7 program. The ONIOM calculations at the HF/3-21G: Amber level in this study are a type of QM/MM calculations of Vreven, T.; Morokuma, K. *J. Chem. Phys.* 2000, 113, 2969-2975 and Frisch, M.; Vreven, T.; Schlegel, H. B.; Morokuma, K. *J. Comput. Chem.* 2003, 24, 760-769, herein both incorporated by reference. Previous reaction coordinate calculations with an active site model of wild-type BChE demonstrate that the HF/3-21G level is adequate for the geometry optimization of this enzymatic reaction system shown by Zhan et al, although the final energy calculations for calculating the energy barriers must be carried out at a higher level. As depicted in Scheme 3, for all of these QM/MM calculations, the same part of the enzyme was included in the QM-treated high layer. So, the QM-treated high layer included (-)-cocaine, key functional groups from the catalytic triad (S198, H438, and E325), and the three residues, i.e., G116, G117, and A199 (or S199 for a particular mutant, see Scheme 4), of the possible oxyanion hole, whereas the entire enzyme structure of BChE was included in the MM-treated low layer. A language computer program was developed to automatically generate the input files for the ONIOM calculations following the MD simulations and subsequent energy minimizations in order to make sure that the atom types used for all low-layer atoms are the same as what were used in the Amber7. During the TS1 geometry optimization using the two-layer ONIOM, the length of a key transition C—O bond was fixed which dominates the reaction coordinate; all of the other transition bond lengths were relaxed. The C and O atoms in the key transition C—O bond are the carbonyl carbon of (-)-cocaine benzoyl ester and the O' atom of S198, respectively, according to the previous reaction coordinate calculations with an active site model of wild-type BChE of Zhan et al.

Most of the MD simulations and QM/MM calculations were performed in parallel on an HP supercomputer (Superdome, with 256 shared-memory processors) at the Center for Computational Sciences, University of Kentucky. Some of the computations were carried out on a 34-processors IBM x335 Linux cluster and SGI Fuel workstations.

29

30



Scheme 4. Schematic representation of the first reaction step for (–)-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation.

Experimental materials. Cloned pfu DNA polymerase and Dpn I endonuclease were obtained from Stratagene (La Jolla, Calif.). <sup>3</sup>H-(–)-cocaine (50 Ci/mmol) was purchased from PerkinElmer Life Sciences (Boston, Mass.). The expression plasmid pRc/CMV was a gift from Dr. O. Lockridge, University of Nebraska Medical Center (Omaha, Nebr.). All oligonucleotides were synthesized by the Integrated DNA Technologies, Inc. The QIAprep Spin Plasmid Miniprep Kit and Qiagen plasmid purification kit and QIAquick PCR purification kit were obtained from Qiagen (Santa Clarita, Calif.). Human embryonic kidney 293T/17 cells were from ATCC (Manassas, Va.). Dulbecco's modified Eagle's medium (DMEM) was purchased from Fisher Scientific (Fairlawn, N.J.). Oligonucleotide primers were synthesized by the Integrated DNA Technologies and Analysis Facility of the University of Kentucky. 3,3',5,5'-Tetramethylbenzidine (TMB) was obtained from Sigma (Saint Louis, Mo.). Anti-butyrylcholinesterase (mouse monoclonal antibody, Product # HAH002-01) was purchased from AntibodyShop (Gentofte, Denmark) and Goat anti-mouse IgG HRP conjugate from Zymed (San Francisco, Calif.).

Site-directed mutagenesis, protein expression, and BChE activity assay. Site-directed mutagenesis of human BChE cDNA was performed by using the QuikChange method of Braman et al. Mutations were generated from wild-type human BChE in a pRc/CMV expression plasmid in accordance with (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, L. M.; Lockridge, O. *Biochemistry* 1997, 36, 2266, (b) Masson, P.; Xie, W.; Froment, M.-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. *Biochim. Biophys. Acta* 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. *Mol. Pharmacol.* 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. *J. Pharmacol. Exp. Ther.* 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. *Eur. J. Biochem.* 2002, 269, 630, herein all incorporated by reference. Using plasmid DNA as template and primers with specific base-pair alterations, mutations were made by polymerase chain reaction with Pfu DNA polymerase, for replication fidelity. The PCR product was treated with Dpn I endonuclease to digest the parental DNA template. Modified plasmid DNA was transformed into *Escherichia coli*, amplified, and purified. The DNA sequences of the mutants were confirmed by DNA sequencing. BChE mutants were expressed in human embryonic kidney cell line 293T/17. Cells were grown to 80-90% confluence in 6-well dishes and then transfected by Lipofectamine 2000 complexes of 4 µg plasmid DNA per each well. Cells were incubated at 37° C. in a CO<sub>2</sub> incubator for 24 hours and cells were moved to 60-mm culture vessel and cultured for four more days. The culture medium [10% fetal bovine serum in Dulbecco's modified Eagle's medium (DMEM)] was harvested for a BChE activity assay. To measure (–)-cocaine and benzoic acid, the product of (–)-cocaine hydrolysis catalyzed by BChE, sensitive radiometric assays were used based on toluene extraction of [<sup>3</sup>H]-(–)-cocaine labeled on its benzene ring in accordance with Sun et al. In brief, to initiate the enzymatic reaction, 100 nCi of [<sup>3</sup>H]-(–)-cocaine was mixed with 100 µl of culture medium. The enzymatic reactions proceeded at room temperature (25° C.) for varying time. The reactions were stopped by adding 300 µl of 0.02 M HCl, which neutralized the liberated benzoic acid while ensuring a positive charge on the residual (–)-cocaine. [<sup>3</sup>H]benzoic acid was extracted by 1 ml of toluene and measured by scintilla-

tion counting. Finally, the measured time-dependent radiometric data were fitted to the kinetic equation so that the catalytic efficiency ( $k_{cat}/K_M$ ) was determined along with the use of an enzyme-linked immunosorbent assay (ELISA) described below.

Enzyme-linked immunosorbent assay (ELISA). The ELISA buffers used in the present study are the same as those described in the literature such as (a) Brock, A.; Mortensen, V.; Loft, A. G. R.; Nergaard-Pedersen, B. *J. Clin. Chem. Clin. Biochem.* 1990, 28, 221-224, (b) Khattab, A. D.; Walker, C. H.; Johnston, G.; Siddiqui, M. K. Saphier, P. W. *Environmental Toxicology and Chemistry* 1994, 13, 1661-1667, herein both incorporated by reference. The coating buffer was 0.1 M sodium carbonate/bicarbonate buffer, pH 9.5. The diluent buffer (EIA buffer) was potassium phosphate monobasic/potassium phosphate monohydrate buffer, pH 7.5, containing 0.9% sodium chloride and 0.1% bovine serum albumin. The washing buffer (PBS-T) was 0.01 M potassium phosphate monobasic/potassium phosphate monohydrate buffer, pH 7.5, containing 0.05% (v/v) Tween-20. All the assays were performed in triplicate. Each well of an ELISA microtiter plate was filled with 100 µl of the mixture buffer consisting of 20 µl culture medium and 80 µl coating buffer. The plate was covered and incubated overnight at 4° C. to allow the antigen to bind to the plate. The solutions were then removed and the wells were washed four times with PBS-T. The washed wells were filled with 200 µl diluent buffer and kept shaking for 1.5 h at room temperature (25° C.). After washing with PBS-T for four times, the wells were filled with 100 µl antibody (1:8000) and were incubated for 1.5 h, followed by washing for four times. Then, the wells were filled with 100 µl goat anti-mouse IgG HRP conjugate complex diluted to a final 1:3000 dilution, and were incubated at room temperature for 1.5 h, followed by washing for four times. The enzyme reactions were started by addition of 100 µl substrate (TMB) solution. The reactions were stopped after 15 min by the addition of 100 µl of 2 M sulfuric acid, and the absorbance was read at 460 nm using a Bio-Rad ELISA plate reader.

Hydrogen bonding revealed by the MD simulations. In accordance with one aspect of the present invention, namely the generation of high-activity mutants of BChE against (–)-cocaine, the present invention includes predicting some possible mutations that can lower the energy of the transition state for the first chemical reaction step (TS1) and, therefore, lower the energy barrier for this critical reaction step. Apparently, a mutant associated with the stronger hydrogen bonding between the carbonyl oxygen of (–)-cocaine benzoyl ester and the oxyanion hole of the BChE mutant in the TS1 structure may potentially have a more stable TS1 structure and, therefore, a higher catalytic activity for (–)-cocaine hydrolysis. Hence, the hydrogen bonding with the oxyanion hole in the TS1 structure is a crucial factor affecting the transition state stabilization and the catalytic activity. The possible effects of some mutations on the hydrogen bonding were examined by performing MD simulations and QM/MM calculations on the TS1 structures for (–)-cocaine hydrolysis catalyzed by the wild-type and various mutants BChE's.

The MD simulation in water was performed for 1 ns or longer to make sure a stable MD trajectory was obtained for each simulated TS1 structure with the wild-type or mutant BChE. The MD trajectories actually became stable quickly, so were the H . . . O distances involved in the potential hydrogen bonds between the carbonyl oxygen of (–)-cocaine and the oxyanion hole of BChE.

Depicted in FIG. 5 are plots of four important H . . . O distances in the MD-simulated TS1 structure versus the simulation time for (–)-cocaine hydrolysis catalyzed by A328W/

Y332A or A199S/A328W/Y332G BChE, along with the root-mean-square deviation (RMSD) of the simulated positions of backbone atoms from those in the corresponding initial structure. Traces D1, D2, and D3 refer to the distances between the carbonyl oxygen of (-)-cocaine and the NH hydrogen of G116, G117, and S199, respectively. Trace D4 is the internuclear distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of the S199 side chain which exists only in A199S/A328W/Y332G BChE. RMSD represents the root-mean-square deviation (in Å) of the simulated positions of the protein backbone atoms from those in the initial structure. The H . . . O distances in the simulated TS1 structures corresponding to the wild-type BChE and the two mutants are summarized in Table 3. The H . . . O distances between the carbonyl oxygen of (-)-cocaine and the peptidic NH hydrogen atoms of G116, G117, and A199 (or S199) of BChE are denoted by D1, D2, and D3, respectively, in Table 2 and FIG. 1. D4 in Table 3 and FIG. 5 refers to the H . . . O distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of S199 side chain in the simulated TS1 structure corresponding to the A199S/A328W/Y332G mutant, mutant (1) (SEQ ID NO: 2).

mutant, the simulated average H . . . O distances with the peptidic NH hydrogen of G117 and A199 are 2.35 and 1.95 Å, respectively. These distances suggest a slightly weaker N—H . . . O hydrogen bond with A199, but a stronger N—H . . . O hydrogen bond with G117, in the simulated TS1 structure corresponding to the A328W/Y332A mutant. The overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme is not expected to change considerably when wild-type BChE is replaced by the A328W/Y332A mutant.

However, the story for the simulated TS1 structure associated with the A199S/A328W/Y332G mutant was remarkably different. As one can see from Scheme 4, FIG. 5, and Table 3, when residue #199 becomes a serine (i.e., S199), the hydroxyl group on the side chain of S199 can also hydrogen-bond to the carbonyl oxygen of (-)-cocaine to form an O—H . . . O hydrogen bond, in addition to the two N—H . . . O hydrogen bonds with the peptidic NH of G117 and S199. The simulated average H . . . O distances with the peptidic NH hydrogen of G117, peptidic NH hydrogen of S199, and hydroxyl hydrogen of S199 are 2.21, 1.94, and 2.15 Å, respectively. Due to the additional O—H . . . O hydrogen

TABLE 3

Summary of the MD-simulated and QM/MM-optimized key distances (in Å) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (-)-cocaine benzoyl ester in the first transition state (TS1).							
Transition State	Method	Distance <sup>a</sup>				Total HBE <sup>b</sup>	
		D1	D2	D3	D4		
TS1 for (-)-cocaine hydrolysis catalyzed by wild-type BChE	MD	Average	4.59	2.91	1.92	-5.5 (-4.6)	
		Maximum	5.73	4.14	2.35		
	QM/MM	Minimum	3.35	1.97	1.61	-4.2	
		Fluctuation	0.35	0.35	0.12		
		Average	4.10	2.21	2.05		
TS1 for (-)-cocaine hydrolysis catalyzed by A328W/Y332A mutant of BChE	MD	Average	3.62	2.35	1.95	-6.2 (-4.9)	
		Maximum	4.35	3.37	3.02		
	QM/MM	Minimum	2.92	1.78	1.61	-3.3	
		Fluctuation	0.23	0.27	0.17		
		Average	3.39	2.05	2.47		
TS1 for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G mutant of BChE	MD	Average	5.30	2.21	1.94	-9.7 (-7.4)	
		Maximum	6.08	3.06	2.47		3.27
	QM/MM	Minimum	4.57	1.71	1.66	1.56	-7.46
		Fluctuation	0.22	0.20	0.13	0.29	
		Average	4.83	2.09	1.91	2.59	

<sup>a</sup>D1, D2, and D3 represent the internuclear distances between the carbonyl oxygen of cocaine benzoyl ester and the NH hydrogen of residues #116 (i.e., G116), #117 (i.e., G117), and #199 (i.e., A199 or S199) of BChE, respectively. D4 is the internuclear distance between the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen of S199 side chain in the A199S/A328W/Y332G mutant.

<sup>b</sup>The total HBE value under MD is the average of the HBE values calculated by using the instantaneous distances in all of the snapshots. The value in parenthesis is the total HBE value calculated by using the MD-simulated average distances. The total HBE value under QM/MM was evaluated by using the QM/MM-optimized distances.

As seen in Table 3, the simulated H . . . O distance D1 is always too long for the peptidic NH of G116 to form a N—H . . . O hydrogen bond with the carbonyl oxygen of (-)-cocaine. In the simulated TS1 structure corresponding to wild-type BChE, the carbonyl oxygen of (-)-cocaine formed a firm N—H . . . O hydrogen bond with the peptidic NH hydrogen atom of A199 residue; the simulated H . . . O distance was 1.61 to 2.35 Å, with an average value of 1.92 Å. Meanwhile, the carbonyl oxygen of (-)-cocaine also had a partial N—H . . . O hydrogen bond with the peptidic NH hydrogen atom of G117 residue; the simulated H . . . O distance was 1.97 to 4.14 Å (the average value: 2.91 Å). In the simulated TS1 structure corresponding to the A328W/Y332A

bond, the overall strength of the hydrogen bonding with the modified oxyanion hole of A199S/A328W/Y332G BChE should be significantly stronger than that of the wild-type and A328W/Y332A BChE's.

To better represent the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in a MD-simulated TS1 structure, the hydrogen bonding energy (HBE) associated with each simulated H . . . O distance was estimated by using the empirical HBE equation implemented in AutoDock 3.0 program suite in accordance with (a) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. *J. Comput. Chem.* 1998, 19, 1639-1662, and based on the general HBE

equation,  $\text{HBE}(r) \approx 5\epsilon r_0^{12}/r^{12} - 6\epsilon r_0^{10}/r^{10}$ , in which  $r$  is the H...O distance in the considered hydrogen bond and  $r_0$  is the minimum value of the H...O distance for which the HBE equation can be used. For the calculation,  $r_0 = 1.52 \text{ \AA}$ , because it is the shortest H...O distance found in all of our MD simulations. The  $\epsilon$  value was determined by using the condition that  $\text{HBE}(r) = -5.0 \text{ kcal/mol}$  when  $r = 1.90 \text{ \AA}$ , herein incorporated by reference. Specifically, for each hydrogen bond with the carbonyl oxygen of (-)-cocaine, a HBE value can be evaluated with each snapshot of the MD-simulated structure. The final HBE of the MD-simulated hydrogen bond is considered to be the average HBE value of all snapshots taken from the stable MD trajectory. The estimated total HBE value for the hydrogen bonds between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in each simulated TS1 structure is given in Table 3.

The HBE for each hydrogen bond was estimated by using the MD-simulated average H...O distance. As seen in Table 3, the total hydrogen-bonding energies (i.e., -4.6, -4.9, and -7.4 kcal/mol for the wild-type, A328W/Y332A, and A199S/A328W/Y332G BChE's, respectively) estimated in this way are systematically higher (i.e., less negative) than the corresponding total hydrogen-bonding energies (i.e., -5.5, -6.2, and -9.7 kcal/mol) estimated in the aforementioned way. However, the two sets of total HBE values are qualitatively consistent in terms of the relative hydrogen-bonding strengths in the three simulated TS1 structures. In particular, the two sets of total HBE values consistently reveal that the overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the simulated TS1 structure for A199S/A328W/Y332G BChE is significantly higher than that for the wild-type and A328W/Y332A BChE's.

Hydrogen bonding based on the QM/MM calculations. The above conclusion obtained from the MD simulations was further examined by carrying out QM/MM calculations. Although this enzymatic reaction system is too large to calculate the QM/MM force constant matrix required in the automated search for a first-order saddle point corresponding to TS1, a partial geometry optimization was performed by fixing the length of the transition C—O bond between the carbonyl carbon of (-)-cocaine and the O' atom of S198 in the QM/MM calculation. This transition C—O bond length dominates the reaction coordinate, according to the previous first-principle reaction coordinate calculations, in accordance with Zhan et al, with an active model of wild-type BChE. In the partial geometry optimization, the transition C—O bond length was fixed at that in the TS1 geometry optimized previously by performing the first-principle reaction coordinate calculation with an active site model of wild-type BChE. This partially optimized geometry should be close to the precisely defined TS1 geometry associated with a first-order saddle point on the potential energy surface, particularly for the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of BChE.

The QM/MM results summarized in Table 3 demonstrate two hydrogen bonds in each of the QM/MM-optimized TS1 structures. Specifically, D2=2.21 Å and D3=2.05 Å in the optimized TS1 structure for wild-type BChE; D2=2.05 Å and D3=2.47 Å in the optimized TS1 structure for the A328W/Y332A mutant; D2=2.09 Å, D3=1.91 Å, and D4=2.59 Å in the optimized TS1 structure for the A199S/A328W/Y332G mutant. Although the QM/MM-optimized individual H...O distances and the estimated HBE values are different from the corresponding values for individual hydrogen bonds, the relative total HBE values (i.e., -4.2, -3.3, and -7.46 kcal/mol for the wild-type, A328W/Y332A, and A199S/A328W/Y332G

BChE's, respectively) estimated from these optimized distances are qualitatively consistent with the corresponding total HBE values (i.e., -4.6, -4.9, and -7.4 kcal/mol) estimated from the MD-simulated average H...O distances.

It should be pointed out that the absolute HBE values estimated in this study are not expected to be accurate, as different computational approaches led different HBE values. Nevertheless, for the purpose of our computational design of a high-activity mutant of BChE, one only needs to know the relative strength of the hydrogen bonding based on the estimated relative total HBE values of different mutants. The three sets of total HBE values (Table 3) estimated from the MD-simulated and QM/MM-optimized H...O distances all consistently demonstrate: (1) the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A BChE should be close to that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by wild-type BChE; (2) the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A BChE.

Catalytic activity. The computational results discussed above suggest that the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by the A199S/A328W/Y332G mutant should be significantly more stable than that by the A328W/Y332A mutant, due to the significant increase of the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme in the TS1 structure. The aforementioned analysis of the literature, namely Sun et al and Hamza et al, also indicate that the first chemical reaction step associated with TS1 should be the rate-determining step of (-)-cocaine hydrolysis catalyzed by a BChE mutant including Y332A or Y332G mutation, although the formation of the prereactive enzyme-substrate complex (ES) is the rate-determining step for (-)-cocaine hydrolysis catalyzed by wild-type BChE. This provides evidence of a clear correlation between the TS1 stabilization and the catalytic activity of A328W/Y332A and A199S/A328W/Y332G BChE's for (-)-cocaine hydrolysis: the more stable the TS1 structure, the lower the energy barrier, and the higher the catalytic activity. Thus, both the MD simulations and QM/MM calculations predict that A199S/A328W/Y332G BChE should have a higher catalytic activity than A328W/Y332A BChE for (-)-cocaine hydrolysis.

The catalytic efficiency ( $k_{cat}/K_M$ ) of A328W/Y332A BChE for (-)-cocaine hydrolysis was reported by Sun et al to be  $\sim 8.6 \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$ , which is  $\sim 9.4$  times of the  $k_{cat}/K_M$  value ( $\sim 9.1 \times 10^5 \text{ M}^{-1} \text{ min}^{-1}$ ) of wild-type BChE. To examine the theoretical prediction of the higher catalytic activity for A199S/A328W/Y332G BChE, A328W/Y332A and A199S/A328W/Y332G mutants of BChE were produced through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with the two mutants and wild-type BChE under the same condition and compared the catalytic efficiency of A328W/Y332A and A199S/A328W/Y332G BChE's to that of the wild-type for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data and the ELISA data, the ratio of the  $k_{cat}/K_M$  value of A328W/Y332A BChE to the  $k_{cat}/K_M$  value of wild-type BChE for (-)-cocaine hydrolysis was determined to be  $\sim 8.6$ . The determined catalytic efficiency ratio of  $\sim 8.6$  is in good agreement with the ratio of  $\sim 9.4$  determined by Sun et al. Further, by using the same experi-

mental protocol, the ratio of the  $k_{cat}/K_M$  value of A199S/A328W/Y332G BChE to the  $k_{cat}/K_M$  value of A328W/Y332A BChE for (-)-cocaine hydrolysis was determined to be  $\sim 7.2$ . These data indicate that the ratio of the  $k_{cat}/K_M$  value of A199S/A328W/Y332G BChE to the  $k_{cat}/K_M$  value of wild-type BChE for (-)-cocaine hydrolysis should be  $\sim 7.2 \times 8.6 \sim 62$  or  $\sim 7.2 \times 9.4 \sim 68$ . Thus, A199S/A328W/Y332G BChE has a  $\sim (65 \pm 6)$ -fold improved catalytic efficiency against (-)-cocaine compared to the wild-type, or A199S/A328W/Y332G BChE has a  $k_{cat}/K_M$  value of  $\sim (5.9 \pm 0.5) \times 10^7$  M  $\text{min}^{-1}$  for (-)-cocaine hydrolysis.

Very recently reported F227A/S287G/A328W/Y332M BChE (i.e., AME-359,  $k_{cat}/K_M = 3.1 \times 10^7$  M  $\text{min}^{-1}$ ) has a  $\sim 34$ -fold improved catalytic efficiency for (-)-cocaine hydrolysis. AME-359 has the highest catalytic efficiency against (-)-cocaine within all of the BChE mutants reported in literature prior to the present study. The catalytic efficiency for our A199S/A328W/Y332G BChE is about two times of that for AME-359 against (-)-cocaine.

Conclusion. Molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations on the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by butyrylcholinesterase (BChE) mutants lead to a better understanding of the effects of protein environment on the transition state stabilization. All of the computational results consistently demonstrate that the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine benzoyl ester and the oxyanion hole of BChE in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by the wild-type and A328W/Y332A BChE's. Thus, both the MD simulations and QM/MM calculations predict that A199S/A328W/Y332G BChE should have a lower energy barrier for the chemical reaction process and, therefore, a higher catalytic efficiency ( $k_{cat}/K_M$ ) for (-)-cocaine hydrolysis; A328W/Y332A BChE has been known to have a  $\sim 9$ -fold improved catalytic efficiency for (-)-cocaine hydrolysis. The theoretical prediction has been confirmed by wet experimental tests showing a  $\sim (65 \pm 6)$ -fold improved catalytic efficiency for A199S/A328W/Y332G BChE against (-)-cocaine compared to the wild-type BChE. The  $k_{cat}/K_M$  value determined for A199S/A328W/Y332G BChE is about two times of the  $k_{cat}/K_M$  value for F227A/S287G/A328W/Y332M BChE (i.e., AME-359, which has the highest catalytic efficiency within all BChE mutants reported prior to the present study) against (-)-cocaine. The encouraging outcome of this study suggests that the transition-state modeling is a promising approach for rational design of high-activity mutants of BChE as a therapeutic treatment of cocaine abuse.

EXPERIMENT 3: MD SIMULATION AND GENERATION OF MUTANT A199S/S287G/A328W/Y332G BChE (MUTANT 3) (SEQ ID NO: 14).

The following simulation and mutant generation relate to A199S/S287G/A328W/Y332G (mutant 3) as a rational design of a high-activity mutant of BChE against (-)-cocaine based on detailed computational modeling of the transition state for the rate-determining step (i.e., the first step of the chemical reaction process). Molecular dynamics (MD) simulations were performed to model the protein environmental effects on the stabilization of the transition-state structure for

BChE-catalyzed hydrolysis of (-)-cocaine as described above for mutant A199S/A328W/Y332G (mutant 1). The simulated results indicate that the transition-state structure can be stabilized much better by the protein environment in A199S/S287G/A328W/Y332G BChE than that in wild-type BChE and in other BChE mutants examined. The computational modeling led to a prediction of the higher catalytic efficiency for the A199S/S287G/A328W/Y332G mutant against (-)-cocaine. The prediction has been confirmed by wet experimental tests showing that the A199S/S287G/A328W/Y332G mutant has a remarkably improved catalytic efficiency against (-)-cocaine. All of the obtained results clearly demonstrate that directly modeling the transition-state structure provides a reliable computational approach to the rational design of a high-activity mutant of BChE against (-)-cocaine.

MD simulations. As with the A199S/A328W/Y332G mutant, when performing any MD simulation on a transition state, in principle, MD simulation using a classical force field (molecular mechanics) can only simulate a stable structure corresponding to a local minimum on the potential energy surface, whereas a transition state during a reaction process is always associated with a first-order saddle point on the potential energy surface.

The initial BChE structures used in the MD simulations were prepared based on our previous MD simulation as above with the prior mutant and the prereactive BChE-(-)-cocaine complex (ES) started from the X-ray crystal structure deposited in the Protein Data Bank (pdb code: 1 POP).

The general procedure for carrying out the MD simulations in water is essentially the same as that used in the computational studies for mutant A199S/A328W/Y332G (mutant 1). Site-directed mutagenesis of human BChE cDNA was performed as described before.

The MD simulation in water was performed as described above, on this mutant. Depicted in FIG. 6 are plots of four important H...O distances in the MD-simulated TS1 structure versus the simulation time for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE, along with the root-mean-square deviation (RMSD) of the simulated positions of backbone atoms from those in the corresponding initial structure. Traces D1, D2, and D3 refer to the distances between the carbonyl oxygen of (-)-cocaine and the NH hydrogen of G116, G117, and S199, respectively. Trace D4 is the internuclear distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of the S199 side chain in A199S/S287G/A328W/Y332G BChE (mutant 3). RMSD represents the root-mean-square deviation (in Å) of the simulated positions of the protein backbone atoms from those in the initial structure.

The H...O distances in the simulated TS1 structures for wild-type BChE and its three mutants are summarized in Table 4. The H...O distances between the carbonyl oxygen of (-)-cocaine and the peptidic NH hydrogen atoms of G116, G117, and A199 (or S199) of BChE are denoted by D1, D2, and D3, respectively, in Table 4 and FIG. 6. D4 in Table 4 and FIG. 6 refers to the H...O distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of S199 side chain in the simulated TS1 structure corresponding to the A199S/S287G/A328W/Y332G mutant.

TABLE 4

Summary of the MD-simulated key distances (in Å) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (-)-cocaine benzoyl ester in the first transition state (TS1).						
Transition State		Distance <sup>a</sup>				Total HBE <sup>b</sup>
		D1	D2	D3	D4	
TS1 structure for (-)-cocaine hydrolysis catalyzed by wild-type BChE	Average	4.59	2.91	1.92		-5.5 (-4.6)
	Maximum	5.73	4.14	2.35		
	Minimum	3.35	1.97	1.61		
	Fluctuation	0.35	0.35	0.12		
TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A mutant of BChE	Average	3.62	2.35	1.95		-6.2 (-4.9)
	Maximum	4.35	3.37	3.02		
	Minimum	2.92	1.78	1.61		
	Fluctuation	0.23	0.27	0.17		
TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332G mutant of BChE	Average	3.60	2.25	1.97		-6.4 (-5.0)
	Maximum	4.24	3.17	2.76		
	Minimum	2.89	1.77	1.62		
	Fluctuation	0.23	0.24	0.17		
TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G mutant of BChE	Average	4.39	2.60	2.01	1.76	-14.0 (-12.0)
	Maximum	5.72	4.42	2.68	2.50	
	Minimum	2.87	1.76	1.62	1.48	
	Fluctuation	0.48	0.36	0.17	0.12	

<sup>a</sup>D1, D2, and D3 represent the internuclear distances between the carbonyl oxygen of cocaine benzoyl ester and the NH hydrogen of residues #116 (i.e., G116), #117 (i.e., G117), and #199 (i.e., A199 or S199) of BChE, respectively. D4 is the internuclear distance between the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen of S199 side chain in the A199S/S287G/A328W/Y332G mutant.

<sup>b</sup>The total HBE value is the average of the HBE values calculated by using the instantaneous distances in all of the snapshots. The value in parenthesis is the total HBE value calculated by using the MD-simulated average distances.


As seen in Table 4, the simulated H . . . O distance D1 is always too long for the peptidic NH of G116 to form a N—H . . . O hydrogen bond with the carbonyl oxygen of (-)-cocaine in all of the simulated TS1 structures. In the simulated TS1 structure for wild-type BChE, the carbonyl oxygen of (-)-cocaine formed a firm N—H . . . O hydrogen bond with the peptidic NH hydrogen atom of A199 residue; the simulated H . . . O distance (D2) was 1.61 to 2.35 Å, with an average D2 value of 1.92 Å. Meanwhile, the carbonyl oxygen of (-)-cocaine also had a partial N—H . . . O hydrogen bond with the peptidic NH hydrogen atom of G117 residue; the simulated H . . . O distance (D3) was 1.97 to 4.14 Å (the average D3 value: 2.91 Å). The average D2 and D3 values became 2.35 and 1.95 Å, respectively, in the simulated TS1 structure for the A328W/Y332A mutant. These distances suggest a slightly weaker N—H . . . O hydrogen bond with A199, but a stronger N—H . . . O hydrogen bond with G117, in the simulated TS1 structure for the A328W/Y332A mutant that the corresponding N—H . . . O hydrogen bonds for the wild-type. The average D2 and D3 values (2.25 and 1.97 Å, respectively) in the simulated TS1 structure for the A328W/Y332G mutant are close to the corresponding distances for the A328W/Y332A mutant. The overall strength of the hydro-

gen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme is not expected to change considerably when wild-type BChE is replaced by the A328W/Y332A or A328W/Y332G mutant.

However, the story for the simulated TS1 structure for the A199S/S287G/A328W/Y332G mutant was remarkably different. As one can see from Scheme 5, FIG. 6, and Table 4, when residue #199 becomes a serine (i.e., S199), the hydroxyl group on the side chain of S199 can also hydrogen-bond to the carbonyl oxygen of (-)-cocaine to form an O—H . . . O hydrogen bond, in addition to the two N—H . . . O hydrogen bonds with the peptidic NH of G117 and S199. The simulated average H . . . O distances with the peptidic NH hydrogen of G117, peptidic NH hydrogen of S199, and hydroxyl hydrogen of S199 are 2.60, 2.01, and 1.76 Å, respectively. Due to the additional O—H . . . O hydrogen bond, the overall strength of the hydrogen bonding with the modified oxyanion hole of A199S/S287G/A328W/Y332G BChE should be significantly stronger than that of wild-type, A328W/Y332A, and A328W/Y332G BChE's.

41

42



Scheme 5. Schematic representation of the transition-state structure for first reaction step for (-)-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation.

To better represent the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in a MD-simulated TS1 structure, the hydrogen bonding energy (HBE) associated with each simulated H...O distance was estimated by using the empirical HBE equation implemented in AutoDock 3.0 program suite of (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, L. M.; Lockridge, O. *Biochemistry* 1997, 36, 2266, (b) Masson, P.; Xie, W.; Froment, M.-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. *Biochim. Biophys. Acta* 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. *Mol. Pharmacol.* 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. *J. Pharmacol. Exp. Ther.* 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. *Eur. J. Biochem.* 2002, 269, 630, herein all incorporated by reference. Specifically, for each hydrogen bond with the carbonyl oxygen of (-)-cocaine, a HBE value can be evaluated with each snapshot of the MD-simulated structure. The final HBE of the MD-simulated hydrogen bond is considered to be the average HBE value of all snapshots taken from the stable MD trajectory. The estimated total HBE value for the hydrogen bonds between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in each simulated TS1 structure is also listed in Table 4.

The HBE for each hydrogen bond was estimated by using the MD-simulated average H...O distance. As seen in Table 4, the total hydrogen-bonding energies (i.e., -4.6, -4.9, -5.0, and -12.0 kcal/mol for the wild-type, A328W/Y332A, A328W/Y332G, and A199S/S287G/A328W/Y332G BChE's, respectively) estimated in this way are systematically higher (i.e., less negative) than the corresponding total hydrogen-bonding energies (i.e., -5.5, -6.2, -6.4, and -14.0 kcal/mol) estimated in the aforementioned way. However, the two sets of total HBE values are qualitatively consistent with each other in terms of the relative hydrogen-bonding strengths in the three simulated TS1 structures. In particular, the two sets of total HBE values consistently reveal that the overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the simulated TS1 structure for A199S/S287G/A328W/Y332G BChE

TS1

is significantly higher than that for wild-type, A328W/Y332A, and A328W/Y332G BChE's.

25 Catalytic activity. The computational results discussed above provides evidence that the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by the A199S/S287G/A328W/Y332G mutant should be significantly more stable than that by the A328W/Y332A or A328W/Y332G mutant, due to the significant increase of the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme in the TS1 structure. The aforementioned analysis of the literature of Sun et al and Hamza et al also indicates that the first chemical reaction step associated with TS1 should be the rate-determining step of (-)-cocaine hydrolysis catalyzed by a BChE mutant including Y332A or Y332G mutation, although the formation of the prereactive enzyme-substrate complex (ES) is the rate-determining step for (-)-cocaine hydrolysis catalyzed by wild-type BChE. This suggests a clear correlation between the TS1 stabilization and the catalytic activity of A328W/Y332A, A328W/Y332G, and A199S/S287G/A328W/Y332G BChE's for (-)-cocaine hydrolysis: the more stable the TS1 structure, the lower the energy barrier, and the higher the catalytic activity. Thus, the MD simulations predict that A199S/S287G/A328W/Y332G BChE should have a higher catalytic activity than A328W/Y332A or A328W/Y332G BChE for (-)-cocaine hydrolysis.

50 The catalytic efficiency ( $k_{cat}/K_M$ ) of A328W/Y332A BChE for (-)-cocaine hydrolysis was reported to be  $\sim 8.6 \times 10^6$  M<sup>-1</sup> min<sup>-1</sup>, which is  $\sim 9.4$  times of the  $k_{cat}/K_M$  value ( $\sim 9.1 \times 10^5$  M<sup>-1</sup> min<sup>-1</sup>) of wild-type BChE for (-)-cocaine hydrolysis. The catalytic efficiency of A328W/Y332G BChE was found to be slightly higher than that of A328W/Y332A BChE for (-)-cocaine hydrolysis. To examine the theoretical prediction of the higher catalytic activity for A199S/S287G/A328W/Y332G BChE, the A328W/Y332A and A199S/S287G/A328W/Y332G mutants of BChE were produced as previously discussed through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with the two mutants and wild-type BChE under the same condition and compared the catalytic efficiency of A328W/Y332A and A199S/S287G/A328W/Y332G BChE's to that of the wild-type for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data and the ELISA data, the ratio of the  $k_{cat}/K_M$  value

of A328W/Y332A BChE to the  $k_{cat}/K_M$  value of wild-type BChE for (-)-cocaine hydrolysis was determined to be ~8.6. The determined catalytic efficiency ratio of ~8.6 is in good agreement with the ratio of ~9.4 determined by Sun et al. Further, by using the same experimental protocol, the ratio of the  $k_{cat}/K_M$  value of A199S/S287G/A328W/Y332G BChE to the  $k_{cat}/K_M$  value of A328W/Y332A BChE for (-)-cocaine hydrolysis was determined to be ~50.6. These data indicate that the ratio of the  $k_{cat}/K_M$  value of A199S/S287G/A328W/Y332G BChE to the  $k_{cat}/K_M$  value of wild-type BChE for (-)-cocaine hydrolysis should be  $\sim 50.6 \times 8.6 \sim 435$  or  $\sim 50.6 \times 9.4 \sim 476$ . Thus, A199S/S287G/A328W/Y332G BChE has a  $\sim(456 \pm 41)$ -fold improved catalytic efficiency against (-)-cocaine compared to the wild-type, or A199S/S287G/A328W/Y332G BChE has a  $k_{cat}/K_M$  value of  $\sim(4.15 \pm 0.37) \times 10^8$  M  $\text{min}^{-1}$  for (-)-cocaine hydrolysis. The catalytic efficiency of A199S/S287G/A328W/Y332G BChE against (-)-cocaine is much higher than that of AME-359 (i.e., F227A/S287G/A328W/Y332M BChE,  $k_{cat}/K_M = 3.1 \times 10^7$  M  $\text{min}^{-1}$ , whose catalytic efficiency against (-)-cocaine is the highest within all of the previously reported BChE mutants) which has a  $\sim 34$ -fold improved catalytic efficiency against (-)-cocaine compared to wild-type BChE.

By using the designed A199S/S287G/A328W/Y332G BChE as an exogenous enzyme in human, when the concentration of this mutant is kept the same as that of the wild-type BChE in plasma, the half-life time of (-)-cocaine in plasma should be reduced from the ~45-90 min to only ~6-12 seconds, considerably shorter than the time required for cocaine crossing the blood-brain barrier to reach CNS. Hence, the outcome of this study could eventually result in a valuable, efficient anti-cocaine medication.

Conclusion. The transition-state simulations demonstrate that the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine benzoyl ester and the oxyanion hole of BChE in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by the wild-type BChE and other BChE mutants simulated. Thus, the MD simulations predict that A199S/S287G/A328W/Y332G BChE should have a significantly lower energy barrier for the chemical reaction process and, therefore, a significantly higher catalytic efficiency ( $k_{cat}/K_M$ ) for (-)-cocaine hydrolysis. The theoretical prediction has been confirmed by wet experimental tests showing a  $\sim(456 \pm 41)$ -fold improved catalytic efficiency for A199S/S287G/A328W/Y332G BChE against (-)-cocaine compared to the wild-type BChE. The  $k_{cat}/K_M$  value determined for A199S/S287G/A328W/Y332G BChE is much higher than the  $k_{cat}/K_M$  value for AME-359 (i.e., F227A/S287G/A328W/Y332M BChE, whose catalytic efficiency against (-)-cocaine is the highest within all of the BChE mutants reported previously in literature) which has a  $\sim 34$ -fold improved catalytic efficiency against (-)-cocaine compared to the wild-type BChE. The outcome of this study provides evidence that the transition-state simulation is a novel and unique approach for rational enzyme redesign and drug discovery.

Although the invention has been described in detail with respect to preferred embodiments thereof, it will be apparent that the invention is capable of numerous modifications and variations, apparent to those skilled in the art, without departing from the spirit and scope of the invention.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 30

<210> SEQ ID NO 1

<211> LENGTH: 1722

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: 14-1 mutant A199S/A328W/Y332G of Human butyrylcholinesterase (BChE)

<400> SEQUENCE: 1

```

gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt      60
tttgggtggca cggtaacagc ctttcttggga attccctatg cacagccacc tcttggtaga      120
cttcgattca aaaagccaca gtctctgacc aagtggctctg atatttgaa tgccacaaaa      180
tatgcaaatt cttgctgtca gaacatagat caaagtttcc caggcttcca tggatcagag      240
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaagt atggattcca      300
gcacctaaac caaaaaatgc cactgtattg atatggattt atgggtgggg ttttcaaact      360
ggaacatcat ctttcatagt ttatgatggc aagtttctgg ctcggttga aagagtattt      420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct      480
gaggctccag ggaacatggg tttatattgat caacagttgg ctcttcagtg ggttcaaaaa      540
aatatagcag ctttgggtgg aaatcctaaa agtgaactc tctttggaga aagttccgga      600
gcagcttcag tttagctgca tttgctttct cctggaagcc attcattgtt caccagagcc      660
attctgcaaa gtggttcctt taatgctcct tgggcggtaa catctcttta tgaagtagg      720

```

-continued

---

```

aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 780
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgtgtgc 840
ccctatggga ctctttgtc agtaaacctt ggtccgaccg tggatggtga tttctcact 900
gacatgccag acatattact tgaacttggg caatttaaaa aaaccagat tttggtgggt 960
gttaataaag atgaagggac atggttttta gtcggtggtg ctctggctt cagcaaagat 1020
aacaatagta tcataactag aaaagaattt caggaagggt taaaaatatt tttccagga 1080
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 1200
cttgccttgg agttcaccaa gaagtctca gaatgggaa ataatgcctt tttctactat 1260
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320
gaaattgaat ttgtcttttg tttacctctg gaaagaagag ataattacac aaaagccgag 1380
gaaattttga gtagatccat agtgaacggt tgggcaaatt ttgcaaaata tgggaatcca 1440
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 1500
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 1560
ttctggacat cttttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 1620
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680
tttaacgatt aactagcaa gaaagaaagt tgtgtgggtc tc 1722

```

```

<210> SEQ ID NO 2
<211> LENGTH: 574
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) aminio acid
sequence modified BChE

```

```

<400> SEQUENCE: 2

```

```

Glu Asp Asp Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met
1      5      10      15
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro
20     25     30
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser
35     40     45
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser
50     55     60
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
65     70     75     80
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn
85     90     95
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp
100    105    110
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr
115    120    125
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met
130    135    140
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro
145    150    155    160
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln
165    170    175

```

-continued

Trp	Val	Gln	Lys	Asn	Ile	Ala	Ala	Phe	Gly	Gly	Asn	Pro	Lys	Ser	Val	180	185	190	
Thr	Leu	Phe	Gly	Glu	Ser	Ser	Gly	Ala	Ala	Ser	Val	Ser	Leu	His	Leu	195	200	205	
Leu	Ser	Pro	Gly	Ser	His	Ser	Leu	Phe	Thr	Arg	Ala	Ile	Leu	Gln	Ser	210	215	220	
Gly	Ser	Phe	Asn	Ala	Pro	Trp	Ala	Val	Thr	Ser	Leu	Tyr	Glu	Ala	Arg	225	230	235	240
Asn	Arg	Thr	Leu	Asn	Leu	Ala	Lys	Leu	Thr	Gly	Cys	Ser	Arg	Glu	Asn	245	250	255	
Glu	Thr	Glu	Ile	Ile	Lys	Cys	Leu	Arg	Asn	Lys	Asp	Pro	Gln	Glu	Ile	260	265	270	
Leu	Leu	Asn	Glu	Ala	Phe	Val	Val	Pro	Tyr	Gly	Thr	Pro	Leu	Ser	Val	275	280	285	
Asn	Phe	Gly	Pro	Thr	Val	Asp	Gly	Asp	Phe	Leu	Thr	Asp	Met	Pro	Asp	290	295	300	
Ile	Leu	Leu	Glu	Leu	Gly	Gln	Phe	Lys	Lys	Thr	Gln	Ile	Leu	Val	Gly	305	310	315	320
Val	Asn	Lys	Asp	Glu	Gly	Thr	Trp	Phe	Leu	Val	Gly	Gly	Ala	Pro	Gly	325	330	335	
Phe	Ser	Lys	Asp	Asn	Asn	Ser	Ile	Ile	Thr	Arg	Lys	Glu	Phe	Gln	Glu	340	345	350	
Gly	Leu	Lys	Ile	Phe	Phe	Pro	Gly	Val	Ser	Glu	Phe	Gly	Lys	Glu	Ser	355	360	365	
Ile	Leu	Phe	His	Tyr	Thr	Asp	Trp	Val	Asp	Asp	Gln	Arg	Pro	Glu	Asn	370	375	380	
Tyr	Arg	Glu	Ala	Leu	Gly	Asp	Val	Val	Gly	Asp	Tyr	Asn	Phe	Ile	Cys	385	390	395	400
Pro	Ala	Leu	Glu	Phe	Thr	Lys	Lys	Phe	Ser	Glu	Trp	Gly	Asn	Asn	Ala	405	410	415	
Phe	Phe	Tyr	Tyr	Phe	Glu	His	Arg	Ser	Ser	Lys	Leu	Pro	Trp	Pro	Glu	420	425	430	
Trp	Met	Gly	Val	Met	His	Gly	Tyr	Glu	Ile	Glu	Phe	Val	Phe	Gly	Leu	435	440	445	
Pro	Leu	Glu	Arg	Arg	Asp	Asn	Tyr	Thr	Lys	Ala	Glu	Glu	Ile	Leu	Ser	450	455	460	
Arg	Ser	Ile	Val	Lys	Arg	Trp	Ala	Asn	Phe	Ala	Lys	Tyr	Gly	Asn	Pro	465	470	475	480
Asn	Glu	Thr	Gln	Asn	Asn	Ser	Thr	Ser	Trp	Pro	Val	Phe	Lys	Ser	Thr	485	490	495	
Glu	Gln	Lys	Tyr	Leu	Thr	Leu	Asn	Thr	Glu	Ser	Thr	Arg	Ile	Met	Thr	500	505	510	
Lys	Leu	Arg	Ala	Gln	Gln	Cys	Arg	Phe	Trp	Thr	Ser	Phe	Phe	Pro	Lys	515	520	525	
Val	Leu	Glu	Met	Thr	Gly	Asn	Ile	Asp	Glu	Ala	Glu	Trp	Glu	Trp	Lys	530	535	540	
Ala	Gly	Phe	His	Arg	Trp	Asn	Asn	Tyr	Met	Met	Asp	Trp	Lys	Asn	Gln	545	550	555	560
Phe	Asn	Asp	Tyr	Thr	Ser	Lys	Lys	Glu	Ser	Cys	Val	Gly	Leu	565	570				

<210> SEQ ID NO 3  
 <211> LENGTH: 1125  
 <212> TYPE: DNA

-continued

---

```

<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: truncated 14-1 (A199S/A328/Y332G) nucleic Acid
      Sequence for modified BChE corresponding to a.a. residues 68-442

<400> SEQUENCE: 3

aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac      60
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc     120
actgtattga tatggattta tgggtgggtt tttcaaactg gaacatcadc tttacatggt     180
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg     240
gtgggtgccc taggattcct agctttgccg ggaatcctg aggctccagg gaacatgggt     300
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga     360
aatcctaaaa gtgtaactct ctttgagaaa agttccggag cagcttcagt tagcctgcat     420
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccttt     480
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacggt gaacttagct     540
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa     600
gatccccaag aaattctctt gaatgaagca tttgtgtgcc cctatgggac tcctttgtca     660
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt     720
gaacttggac aatttaaaaa aaccagatt ttggtgggtg ttaataaaga tgaagggaca     780
tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga     840
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa     900
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag     960
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttggg gttcaccaag    1020
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa    1080
cttcctgtgc cagaatggat gggagtgatg catggctatg aaatt                          1125

```

```

<210> SEQ ID NO 4
<211> LENGTH: 375
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: truncated 14-1 mutant (A199S/A328/Y332G) amino
      acid sequence of modified BChE

```

```

<400> SEQUENCE: 4

Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn
1           5           10           15

Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile
20          25          30

Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly
35          40          45

Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys
50          55          60

Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg
65          70          75          80

Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro
85          90          95

Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln
100         105         110

Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe
115         120         125

```

-continued

Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro  
 130 135 140  
 Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe  
 145 150 155 160  
 Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr  
 165 170 175  
 Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu  
 180 185 190  
 Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn  
 195 200 205  
 Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly  
 210 215 220  
 Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu  
 225 230 235 240  
 Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys  
 245 250 255  
 Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys  
 260 265 270  
 Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys  
 275 280 285  
 Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe  
 290 295 300  
 His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu  
 305 310 315 320  
 Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu  
 325 330 335  
 Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr  
 340 345 350  
 Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly  
 355 360 365  
 Val Met His Gly Tyr Glu Ile  
 370 375

&lt;210&gt; SEQ ID NO 5

&lt;211&gt; LENGTH: 966

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) BChE nucleic acid sequence corresponding to a.a. residues 117-438

&lt;400&gt; SEQUENCE: 5

ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcggggt 60  
 gaaagagtta ttgtagtgtc aatgaactat aggggtgggtg ccctaggatt cttagctttg 120  
 ccaggaaate ctgaggtccc agggaacatg gggttatttg atcaacagtt ggetcttcag 180  
 tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240  
 gaaagtccg gagcagcttc agttagcctg catttgcttt ctctggaag ccattcattg 300  
 ttcaccagag ccattctgca aagtgggtcc tttaatgctc cttgggcggg aacatctctt 360  
 tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420  
 gagactgaaa taatcaagtg tcttagaanaa aaagatcccc aagaaattct tctgaatgaa 480  
 gcatttggtg tccccatagg gactcctttg tcagttaaact ttggtccgac cgtggatggt 540  
 gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaccag 600

-continued

---

```

attttggtgg gtgtaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc 660
ttcagcaaag ataacaatag tatkataact agaaaagaat ttcaggaagg tttaaaaata 720
ttttttccag gactgagtg gtttggaag gaatccatcc ttttcatta cacagactgg 780
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgtgt tggggattat 840
aatttcatat gccttgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900
ttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960
atgcat 966

```

```

<210> SEQ ID NO 6
<211> LENGTH: 322
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) BChE a.a.
        residues 117-438

```

```

<400> SEQUENCE: 6

```

```

Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe
1          5          10          15
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val
20          25          30
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly
35          40          45
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys
50          55          60
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly
65          70          75          80
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly
85          90          95
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe Asn
100         105         110
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu
115         120         125
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile
130         135         140
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu
145         150         155         160
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly Pro
165         170         175
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu
180         185         190
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp
195         200         205
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp
210         215         220
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile
225         230         235         240
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His
245         250         255
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala
260         265         270
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu
275         280         285

```

-continued

Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr  
 290 295 300

Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val  
 305 310 315 320

Met His

<210> SEQ ID NO 7

<211> LENGTH: 1722

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: 14-2 mutant (A199S/F227A/A328W/Y332G) BChE,  
 full nucleic acid sequence

<400> SEQUENCE: 7

```

gaagatgaca tcataattgc aacaagaat ggaaaagtca gagggatgaa cttgacagtt      60
tttgggtggca cggtaacagc ctttcttggga attccctatg cacagccacc tcttggtaga    120
cttcgattca aaaagccaca gtctctgacc aagtggctctg atatttggaa tgccacaaaa    180
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag     240
atgtggaacc caaacactga cctcagttaa gactgtttat atctaaatgt atggattcca     300
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtgggtgg ttttcaaact    360
ggaacatcat ctttacctgt ttatgatggc aagtttctgg ctcggttga aagagtattt     420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct     480
gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa    540
aatatagcag ctttgggtgg aaatcctaaa agtghtaactc tctttggaga aagtcccgga    600
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc    660
attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg     720
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata     780
atcaagtgtc ttagaaataa agatcccaa gaaattcttc tgaatgaagc atttgttgtc     840
ccctatggga ctctttgtc agtaaaactt ggtccgaccg tggatggtga ttttctcact     900
gacatgccag acatattact tgaacttggc caatttaaaa aaaccagat tttggtgggt     960
gttaataaag atgaagggac atgggtttta gtcggtggtg ctctctgctt cagcaaagat    1020
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt tttccagga    1080
gtgagtgagt ttgaaaagga atccatcctt tttcattaca cagactgggt agatgatcag    1140
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc    1200
cctgccttgg agttcaccaa gaagtctca gaatgggaa ataatgcctt tttctactat    1260
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat    1320
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag    1380
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca    1440
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat    1500
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga    1560
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa    1620
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa    1680
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc                          1722

```

-continued

---

<210> SEQ ID NO 8  
 <211> LENGTH: 574  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 14-2 mutant (A199S/F227A/A328W/Y332G), full amino acid sequence

<400> SEQUENCE: 8

Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met  
 1 5 10 15  
 Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro  
 20 25 30  
 Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser  
 35 40 45  
 Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser  
 50 55 60  
 Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu  
 65 70 75 80  
 Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn  
 85 90 95  
 Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp  
 100 105 110  
 Ile Tyr Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr  
 115 120 125  
 Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met  
 130 135 140  
 Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro  
 145 150 155 160  
 Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln  
 165 170 175  
 Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val  
 180 185 190  
 Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu  
 195 200 205  
 Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser  
 210 215 220  
 Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg  
 225 230 235 240  
 Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn  
 245 250 255  
 Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile  
 260 265 270  
 Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val  
 275 280 285  
 Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp  
 290 295 300  
 Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly  
 305 310 315 320  
 Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly  
 325 330 335  
 Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu  
 340 345 350  
 Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser  
 355 360 365

-continued

---

Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn  
 370 375 380

Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys  
 385 390 395 400

Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala  
 405 410 415

Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu  
 420 425 430

Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu  
 435 440 445

Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser  
 450 455 460

Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro  
 465 470 475 480

Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr  
 485 490 495

Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr  
 500 505 510

Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys  
 515 520 525

Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys  
 530 535 540

Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln  
 545 550 555 560

Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu  
 565 570

<210> SEQ ID NO 9  
 <211> LENGTH: 1125  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 14-2 mutant (A199/F227A/A328W/Y322G) BChE  
 nucleic acid sequence for a.a. residues 68-442

<400> SEQUENCE: 9

```

aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac      60
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc      120
actgtattga tatggattta tgggtgggtg tttcaaactg gaacatcatc tttacatggt      180
tatgatggca agtttctggc tcgggttgaa agagtattg tagtgtcaat gaactatagg      240
gtgggtgccc taggattcct agccttgcca ggaaatcctg aggctccagg gaacatgggt      300
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatgcagc ctttggtgga      360
aatcctaaaa gtgtaactct ctttgagaaa agttccggag cagcttcagt tagcctgcat      420
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct      480
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacgtt gaacttagct      540
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa      600
gatccccaag aaattcttct gaatgaagca tttgttgtcc cctatgggac tcctttgtca      660
gtaaactttg gtccgaccgt ggatgggtgat tttctcactg acatgccaga catattactt      720
gaacttggac aatttaaaaa aaccagatt ttggtgggtg ttaataaaga tgaagggaca      780
tggtttttag tcggtggtgc tcttggttc agcaaagata acaatagtat cataactaga      840
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa      900

```

-continued

---

```

tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag    960
gccttggggtg atgttgttgg ggattataat ttcatatgcc ctgccttggg gttcaccaag    1020
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa    1080
cttcctgtggc cagaatggat gggagtgatg catggctatg aaatt                    1125

```

```

<210> SEQ ID NO 10
<211> LENGTH: 375
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-2 mutant (A199S/F227A/A328W/Y332G) BChE,
      amino acid sequence for residues 68-442

```

```

<400> SEQUENCE: 10

```

```

Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn
1           5           10           15
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile
20          25          30
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly
35          40          45
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys
50          55          60
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg
65          70          75          80
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro
85          90          95
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln
100         105         110
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe
115        120        125
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro
130        135        140
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala
145        150        155        160
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr
165        170        175
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu
180        185        190
Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn
195        200        205
Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly
210        215        220
Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu
225        230        235        240
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys
245        250        255
Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys
260        265        270
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys
275        280        285
Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe
290        295        300
His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu
305        310        315        320

```

-continued

Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu  
 325 330 335

Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr  
 340 345 350

Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly  
 355 360 365

Val Met His Gly Tyr Glu Ile  
 370 375

<210> SEQ ID NO 11  
 <211> LENGTH: 966  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 14-2 mutant (A199S/F227A/A328W/Y332G) BChE  
 nucleic acid sequence for residues 117-438

<400> SEQUENCE: 11

```

ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcggggt    60
gaaagagtta ttgtagtgtc aatgaactat aggggtgggtg ccctaggatt cttagctttg    120
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag    180
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga    240
gaaagtccg gagcagcttc agttagcctg catttgcttt ctctggaag ccattcattg    300
ttcaccagag ccattctgca aagtggttcc gctaagtctc cttgggcggg aacatctctt    360
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat    420
gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa    480
gcatttgtyt tccccatag gactcctttg tcagtaaact ttggtccgac cgtggatggt    540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaaccag    600
atthtggtyg gtgtaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc    660
ttcagcaaag ataacaatag taccataact agaaaagaat ttcaggaagg tttaaaaata    720
ttttttccag gagtgagtga gtttggaag gaatccatcc tttttcatta cacagactgg    780
gtagatgata agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat    840
aatttcatat gcctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc    900
tttttctact atthtgaaca ccgatctccc aaacttccgt ggccagaatg gatgggagtg    960
atgcat
  
```

<210> SEQ ID NO 12  
 <211> LENGTH: 322  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 14-2 (A199S/F227A/A328W/Y332G) a.a residues  
 117-438

<400> SEQUENCE: 12

Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe  
 1 5 10 15

Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val  
 20 25 30

Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly  
 35 40 45

Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys

-continued

50	55	60
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 65 70 75 80		
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 85 90 95		
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn 100 105 110		
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 115 120 125		
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 130 135 140		
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu 145 150 155 160		
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly Pro 165 170 175		
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 180 185 190		
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 195 200 205		
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp 210 215 220		
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 225 230 235 240		
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 245 250 255		
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 260 265 270		
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu 275 280 285		
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 290 295 300		
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val 305 310 315 320		
Met His		

<210> SEQ ID NO 13  
 <211> LENGTH: 1722  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE  
 nucleic acid sequence

<400> SEQUENCE: 13

gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt	60
tttgggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga	120
cttcgattca aaaagccaca gtctctgacc aagtgggtctg atatttggaa tgccacaaaa	180
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag	240
atgtggaacc caaacactga cctcagttaa gactgtttat atctaaatgt atggattcca	300
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtgggtgg ttttcaaact	360
ggaacatcat ctttacatgt ttatgatggc aagttttctg ctcgggttga aagagttatt	420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct	480

-continued

---

```

gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa 540
aatatagcag cctttggtgg aaatcctaaa agtgttaactc tctttggaga aagttccgga 600
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattggt caccagagcc 660
attctgcaaa gtggttcctt taatgctcct tgggcggtaa catctcttta tgaagctagg 720
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 780
atcaagtgtc ttagaataaa agatcccaaa gaaattcttc tgaatgaagc atttgtgtgc 840
ccctatggga ctcccttggg tgtaaacctt ggtccgaccg tggatggtga ttttctcact 900
gacatgccag acatattact tgaacttggg caatttaaaa aaaccagat tttggtgggt 960
gttaataaag atgaagggac atggttttta gtcggtggtg ctctctggctt cagcaaagat 1020
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt tttccagga 1080
gtgagtgagt ttggaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 1200
cctgccttgg agttcaccaa gaagtctca gaatggggaa ataatgcctt tttctactat 1260
tttgaacacc gatcctcaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 1380
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 1440
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 1500
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 1560
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 1620
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680
tttaacgatt aactagcaa gaaagaaagt tgtgtgggtc tc 1722

```

&lt;210&gt; SEQ ID NO 14

&lt;211&gt; LENGTH: 574

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE amino acid sequence

&lt;400&gt; SEQUENCE: 14

```

Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met
1           5           10           15
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro
20          25          30
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser
35          40          45
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser
50          55          60
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
65          70          75          80
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn
85          90          95
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp
100         105         110
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr
115         120         125
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met
130         135         140

```

-continued

---

Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro  
 145 150 155 160  
 Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln  
 165 170 175  
 Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val  
 180 185 190  
 Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu  
 195 200 205  
 Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser  
 210 215 220  
 Gly Ser Phe Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg  
 225 230 235 240  
 Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn  
 245 250 255  
 Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile  
 260 265 270  
 Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val  
 275 280 285  
 Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp  
 290 295 300  
 Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly  
 305 310 315 320  
 Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly  
 325 330 335  
 Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu  
 340 345 350  
 Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser  
 355 360 365  
 Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn  
 370 375 380  
 Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys  
 385 390 395 400  
 Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala  
 405 410 415  
 Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu  
 420 425 430  
 Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu  
 435 440 445  
 Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser  
 450 455 460  
 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro  
 465 470 475 480  
 Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr  
 485 490 495  
 Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr  
 500 505 510  
 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys  
 515 520 525  
 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys  
 530 535 540  
 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln  
 545 550 555 560

-continued

---

Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu  
565 570

<210> SEQ ID NO 15  
 <211> LENGTH: 1125  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE  
 nucleic acid sequence for amino acid residues 68-442

<400> SEQUENCE: 15

```

aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac    60
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc    120
actgtattga tatggattta tgggtgggtg tttcaaactg gaacatcatc tttacatggt    180
tatgatggca agtttctggc tcgggttgaa agagtattg tagtgtcaat gaactatagg    240
gtgggtgccc taggattcct agccttgcca ggaaatcctg aggctccagg gaacatgggt    300
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga    360
aatcctaaaa gtgtaactct ctttgagaaa agttccggag cagcttcagt tagcctgcat    420
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccttt    480
aatgctcctt ggggggtaac atctctttat gaagctagga acagaacggt gaacttagct    540
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa    600
gatccccaag aaattcttct gaatgaagca tttgttgtcc cctatgggac tcctttgggt    660
gtaaactttg gtccgaccgt ggatggatg tttctcactg acatgccaga catattactt    720
gaacttggac aatttaaaaa aaccagatt ttggtgggtg ttaataaaga tgaagggaca    780
tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga    840
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa    900
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag    960
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttggg gttcaccaag   1020
aagtctcag aatggggaaa taatgctttt ttctactatt ttgaacaccg atcctccaaa   1080
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt                               1125

```

<210> SEQ ID NO 16  
 <211> LENGTH: 375  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE  
 amino acid sequence for residues 68-442

<400> SEQUENCE: 16

```

Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn
1           5           10           15
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile
20          25          30
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly
35          40          45
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys
50          55          60
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg
65          70          75          80
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro

```

-continued

85			90			95									
Gly	Asn	Met	Gly	Leu	Phe	Asp	Gln	Gln	Leu	Ala	Leu	Gln	Trp	Val	Gln
			100					105					110		
Lys	Asn	Ile	Ala	Ala	Phe	Gly	Gly	Asn	Pro	Lys	Ser	Val	Thr	Leu	Phe
		115					120					125			
Gly	Glu	Ser	Ser	Gly	Ala	Ala	Ser	Val	Ser	Leu	His	Leu	Leu	Ser	Pro
	130					135					140				
Gly	Ser	His	Ser	Leu	Phe	Thr	Arg	Ala	Ile	Leu	Gln	Ser	Gly	Ser	Phe
	145				150					155					160
Asn	Ala	Pro	Trp	Ala	Val	Thr	Ser	Leu	Tyr	Glu	Ala	Arg	Asn	Arg	Thr
				165					170						175
Leu	Asn	Leu	Ala	Lys	Leu	Thr	Gly	Cys	Ser	Arg	Glu	Asn	Glu	Thr	Glu
			180					185					190		
Ile	Ile	Lys	Cys	Leu	Arg	Asn	Lys	Asp	Pro	Gln	Glu	Ile	Leu	Leu	Asn
		195					200					205			
Glu	Ala	Phe	Val	Val	Pro	Tyr	Gly	Thr	Pro	Leu	Gly	Val	Asn	Phe	Gly
	210						215				220				
Pro	Thr	Val	Asp	Gly	Asp	Phe	Leu	Thr	Asp	Met	Pro	Asp	Ile	Leu	Leu
	225				230					235					240
Glu	Leu	Gly	Gln	Phe	Lys	Lys	Thr	Gln	Ile	Leu	Val	Gly	Val	Asn	Lys
				245					250					255	
Asp	Glu	Gly	Thr	Trp	Phe	Leu	Val	Gly	Gly	Ala	Pro	Gly	Phe	Ser	Lys
			260					265					270		
Asp	Asn	Asn	Ser	Ile	Ile	Thr	Arg	Lys	Glu	Phe	Gln	Glu	Gly	Leu	Lys
		275					280					285			
Ile	Phe	Phe	Pro	Gly	Val	Ser	Glu	Phe	Gly	Lys	Glu	Ser	Ile	Leu	Phe
	290						295				300				
His	Tyr	Thr	Asp	Trp	Val	Asp	Asp	Gln	Arg	Pro	Glu	Asn	Tyr	Arg	Glu
	305				310					315					320
Ala	Leu	Gly	Asp	Val	Val	Gly	Asp	Tyr	Asn	Phe	Ile	Cys	Pro	Ala	Leu
				325					330					335	
Glu	Phe	Thr	Lys	Lys	Phe	Ser	Glu	Trp	Gly	Asn	Asn	Ala	Phe	Phe	Tyr
			340					345					350		
Tyr	Phe	Glu	His	Arg	Ser	Ser	Lys	Leu	Pro	Trp	Pro	Glu	Trp	Met	Gly
		355					360					365			
Val	Met	His	Gly	Tyr	Glu	Ile									
	370					375									

&lt;210&gt; SEQ ID NO 17

&lt;211&gt; LENGTH: 966

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE  
nucleic acid sequence for amino acid residues 117-438

&lt;400&gt; SEQUENCE: 17

```

ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcggggt      60
gaaagagtta ttgtagtgtc aatgaactat aggggtgggtg ccctaggatt cttagctttg      120
ccaggaaatc ctgaggctcc agggaacatg gggtttatttg atcaacagtt ggctcttcag      180
tgggttcaaa aaaatatagc agcctttggt ggaaatceta aaagtgtaac tctctttgga      240
gaaagtcccg gaggcagctc agttagcctg catttgcttt ctctggaag ccattcattg      300
ttcaccagag ccattctgca aagtgggtcc tttaatgctc cttggggcgtt aacatctctt      360

```

-continued

---

```

tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420
gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa 480
gcatttggtg tccccatagg gactcctttg ggtgtaaact ttggtccgac cgtggatggt 540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaaccag 600
atthttggtg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc 660
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata 720
ttttttccag gaggtagtga gtttggaag gaatccatcc tttttcatta cacagactgg 780
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgtgtg tggggattat 840
aatttcatat gcctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900
tttttctact atthttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960
atgcat 966

```

```

<210> SEQ ID NO 18
<211> LENGTH: 322
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE
        amino acid sequence for residues 117-438

```

```

<400> SEQUENCE: 18

```

```

Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe
 1             5             10             15
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val
          20          25          30
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly
          35          40          45
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys
          50          55          60
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly
          65          70          75          80
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly
          85          90          95
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe Asn
          100         105         110
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu
          115         120         125
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile
          130         135         140
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu
          145         150         155         160
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro
          165         170         175
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu
          180         185         190
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp
          195         200         205
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp
          210         215         220
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile
          225         230         235         240
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His

```



-continued

---

```

ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 1620
tgggagtgga aagcaggatt ccacgcctgg aacaattaca tgatggactg gaaaaatcaa 1680
ttaaagcatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722

```

```

<210> SEQ ID NO 20
<211> LENGTH: 574
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)
      BChE amino acid sequence

```

```

<400> SEQUENCE: 20

```

```

Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met
1           5           10           15
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro
20          25          30
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser
35          40          45
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser
50          55          60
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
65          70          75          80
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn
85          90          95
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp
100         105        110
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr
115        120        125
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met
130        135        140
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro
145        150        155        160
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln
165        170        175
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val
180        185        190
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu
195        200        205
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser
210        215        220
Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg
225        230        235        240
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn
245        250        255
Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile
260        265        270
Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val
275        280        285
Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp
290        295        300
Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly
305        310        315        320
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly
325        330        335

```

-continued

Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu  
 340 345 350  
 Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser  
 355 360 365  
 Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn  
 370 375 380  
 Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys  
 385 390 395 400  
 Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala  
 405 410 415  
 Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu  
 420 425 430  
 Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu  
 435 440 445  
 Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser  
 450 455 460  
 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro  
 465 470 475 480  
 Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr  
 485 490 495  
 Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr  
 500 505 510  
 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys  
 515 520 525  
 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys  
 530 535 540  
 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln  
 545 550 555 560  
 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu  
 565 570

&lt;210&gt; SEQ ID NO 21

&lt;211&gt; LENGTH: 1125

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)  
 BChE nucleic acid sequence for amino acid residues 68-442

&lt;400&gt; SEQUENCE: 21

```

aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac      60
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc     120
actgtattga tatggattta tgggtggtgt tttcaaaactg gaacatcadc tttacatggt     180
tatgatggca agtttctggc tcgggttgaa agagtatttg tagtgtcaat gaactatagg     240
gtgggtgccc taggattcct agccttgcca ggaaatcctg aggctccagg gaacatgggt     300
ttatttgate aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga     360
aatcctaaaa gtgtaactct ctttgaggaa agttccggag cagcttcagt tagcctgcat     420
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct     480
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacggt gaacttagct     540
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa     600
gatccccaag aaattcttct gaatgaagca tttgtgttcc cctatgggac tcctttgggt     660
  
```

-continued

---

```

gtaaactttg gtccgaccgt ggatggatgat tttctcactg acatgccaga catattactt 720
gaacttggac aatttaaaaa aaccagatt ttggtgggtg ttaataaaga tgaagggaca 780
tggtttttag tcggtgggtc tcctggcttc agcaaagata acaatagtat cataactaga 840
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 900
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 960
gccttgggtg atgttggtgg ggattataat ttcatatgcc ctgccttggg gttcaccaag 1020
aagtctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa 1080
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 1125

```

&lt;210&gt; SEQ ID NO 22

&lt;211&gt; LENGTH: 375

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

```

<223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)
      EChE amino acid sequence for residues 68-442

```

&lt;400&gt; SEQUENCE: 22

```

Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn
 1             5             10             15
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile
          20             25             30
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly
          35             40             45
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys
          50             55             60
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg
 65             70             75             80
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro
          85             90             95
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln
          100            105            110
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe
          115            120            125
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro
          130            135            140
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala
          145            150            155            160
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr
          165            170            175
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu
          180            185            190
Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn
          195            200            205
Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly
          210            215            220
Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu
          225            230            235            240
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys
          245            250            255
Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys
          260            265            270
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys

```

-continued

275					280					285					
Ile	Phe	Phe	Pro	Gly	Val	Ser	Glu	Phe	Gly	Lys	Glu	Ser	Ile	Leu	Phe
	290					295					300				
His	Tyr	Thr	Asp	Trp	Val	Asp	Asp	Gln	Arg	Pro	Glu	Asn	Tyr	Arg	Glu
305					310					315					320
Ala	Leu	Gly	Asp	Val	Val	Gly	Asp	Tyr	Asn	Phe	Ile	Cys	Pro	Ala	Leu
				325					330					335	
Glu	Phe	Thr	Lys	Lys	Phe	Ser	Glu	Trp	Gly	Asn	Asn	Ala	Phe	Phe	Tyr
			340					345						350	
Tyr	Phe	Glu	His	Arg	Ser	Ser	Lys	Leu	Pro	Trp	Pro	Glu	Trp	Met	Gly
		355					360					365			
Val	Met	His	Gly	Tyr	Glu	Ile									
	370				375										

<210> SEQ ID NO 23  
 <211> LENGTH: 966  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)  
 BChE nucleic acid sequence for amino acid residues 117-438

<400> SEQUENCE: 23

```

ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcggggt    60
gaaagagtta ttgtagtgtc aatgaactat aggggtgggtg ccctaggatt cttagctttg    120
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag    180
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga    240
gaaagtcccg gagcagcttc agttagcctg catttgcttt ctctggaag ccattcattg    300
ttcaccagag ccattctgca aagtggttcc gctaatgctc cttgggcggg aacatctctt    360
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat    420
gagactgaaa taatcaagtg tcttagaagt aaagatcccc aagaaattct tctgaatgaa    480
gcatttgttg tcccctatgg gactcctttg ggtgtaaact ttggtccgac cgtggatggg    540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaaccag    600
atthttggtg gtgtaataaa agatgaaggg acatggtttt tagtcggtgg tgctcctggc    660
ttcagcaaaag ataacaatag taccataact agaaaagaat ttcaggaagg tttaaaaata    720
tttttccag gagtgagtga gtttgaaaag gaatccatcc tttttcatta cacagactgg    780
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgtgtg tggggattat    840
aatttcatat gcctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc    900
tttttctact atthttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg    960
atgcat                                          966

```

<210> SEQ ID NO 24  
 <211> LENGTH: 322  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)  
 BChE amino acid sequence for residues 117-438

<400> SEQUENCE: 24

Gly	Phe	Gln	Thr	Gly	Thr	Ser	Ser	Leu	His	Val	Tyr	Asp	Gly	Lys	Phe
1			5					10						15	

-continued

Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val  
                   20                                  25                                  30  
 Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly  
                   35                                  40                                  45  
 Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys  
                   50                                  55                                  60  
 Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly  
                   65                                  70                                  75                                  80  
 Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly  
                                   85                                  90                                  95  
 Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn  
                   100                                  105                                  110  
 Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu  
                   115                                  120                                  125  
 Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile  
                   130                                  135                                  140  
 Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu  
                   145                                  150                                  155                                  160  
 Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro  
                                   165                                  170                                  175  
 Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu  
                   180                                  185                                  190  
 Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp  
                   195                                  200                                  205  
 Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp  
                   210                                  215                                  220  
 Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile  
                   225                                  230                                  235                                  240  
 Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His  
                                   245                                  250                                  255  
 Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala  
                   260                                  265                                  270  
 Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu  
                   275                                  280                                  285  
 Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr  
                   290                                  295                                  300  
 Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val  
                   305                                  310                                  315                                  320  
 Met His

<210> SEQ ID NO 25  
 <211> LENGTH: 1722  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)  
                   Bche nucleic acid sequence

<400> SEQUENCE: 25

gaagatgaca tcataattgc aacaagaat ggaaaagtca gagggatgaa cttgacagtt     60  
 tttggtggca cggtaacagc ctttcttgga attcctatg cacagccacc tcttggtaga     120  
 cttcogattca aaaagccaca gtctctgacc aagtggctctg atatttggaa tgccacaaaa     180  
 tatgcaaatt cttgtctgca gaacatagat caaagttttc caggcttcca tggatcagag     240  
 atgtggaacc caaacactga cctcagttaa gactgtttat atctaagtgt atggattcca     300

-continued

---

```

gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 360
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcggttga aagagttatt 420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 480
gaggctccag ggaacatggg tttatattgat caacagttgg ctcttcagtg ggttcaaaaa 540
aatatagcag cctttggtgg aaatcctaaa agtctaactc tctttggaga aagttccgga 600
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattggt caccagagcc 660
attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg 720
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 780
atcaagtgtc ttagaataaa agatccoccaa gaaattcttc tgaatgaagc atttgtgtgc 840
ccctatggga ctcccttggg tgtaaacctt ggtccgaccg tggatggtga ttttctcact 900
gacatgccag acatattact tgaacttggg caatttaaaa aaaccagat tttggtgggt 960
gttaataaag atgaagggac atggttttta gtctatggtg ctctggtctt cagcaaagat 1020
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 1080
gtgagtgagt ttgaaaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 1200
cctgccttgg agttcaccaa gaagtctca gaatggggaa ataatgcctt tttctactat 1260
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320
gacattgaat ttgtcttttg tttacctctg gaaagaagag ataattacac aaaagccgag 1380
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 1440
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaaat 1500
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 1560
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 1620
tgggagtgga aagcaggatt ccacgctggg aacaattaca tgatggactg gaaaaatcaa 1680
ttaaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722

```

&lt;210&gt; SEQ ID NO 26

&lt;211&gt; LENGTH: 574

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)  
 BChE amino acid sequence

&lt;400&gt; SEQUENCE: 26

```

Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met
1           5           10           15
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro
20          25          30
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser
35          40          45
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser
50          55          60
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
65          70          75          80
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn
85          90          95
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp

```

-continued

100					105					110					
Ile	Tyr	Gly	Gly	Gly	Phe	Gln	Thr	Gly	Thr	Ser	Ser	Leu	His	Val	Tyr
		115					120					125			
Asp	Gly	Lys	Phe	Leu	Ala	Arg	Val	Glu	Arg	Val	Ile	Val	Val	Ser	Met
	130					135					140				
Asn	Tyr	Arg	Val	Gly	Ala	Leu	Gly	Phe	Leu	Ala	Leu	Pro	Gly	Asn	Pro
	145					150					155				160
Glu	Ala	Pro	Gly	Asn	Met	Gly	Leu	Phe	Asp	Gln	Gln	Leu	Ala	Leu	Gln
				165					170					175	
Trp	Val	Gln	Lys	Asn	Ile	Ala	Ala	Phe	Gly	Gly	Asn	Pro	Lys	Ser	Val
			180						185					190	
Thr	Leu	Phe	Gly	Glu	Ser	Ser	Gly	Ala	Ala	Ser	Val	Ser	Leu	His	Leu
		195					200						205		
Leu	Ser	Pro	Gly	Ser	His	Ser	Leu	Phe	Thr	Arg	Ala	Ile	Leu	Gln	Ser
		210				215					220				
Gly	Ser	Ala	Asn	Ala	Pro	Trp	Ala	Val	Thr	Ser	Leu	Tyr	Glu	Ala	Arg
	225					230					235				240
Asn	Arg	Thr	Leu	Asn	Leu	Ala	Lys	Leu	Thr	Gly	Cys	Ser	Arg	Glu	Asn
				245					250					255	
Glu	Thr	Glu	Ile	Ile	Lys	Cys	Leu	Arg	Asn	Lys	Asp	Pro	Gln	Glu	Ile
			260						265					270	
Leu	Leu	Asn	Glu	Ala	Phe	Val	Val	Pro	Tyr	Gly	Thr	Pro	Leu	Gly	Val
		275					280						285		
Asn	Phe	Gly	Pro	Thr	Val	Asp	Gly	Asp	Phe	Leu	Thr	Asp	Met	Pro	Asp
		290				295					300				
Ile	Leu	Leu	Glu	Leu	Gly	Gln	Phe	Lys	Lys	Thr	Gln	Ile	Leu	Val	Gly
	305					310					315				320
Val	Asn	Lys	Asp	Glu	Gly	Thr	Trp	Phe	Leu	Val	Tyr	Gly	Ala	Pro	Gly
				325					330					335	
Phe	Ser	Lys	Asp	Asn	Asn	Ser	Ile	Ile	Thr	Arg	Lys	Glu	Phe	Gln	Glu
			340						345					350	
Gly	Leu	Lys	Ile	Phe	Phe	Pro	Gly	Val	Ser	Glu	Phe	Gly	Lys	Glu	Ser
		355					360					365			
Ile	Leu	Phe	His	Tyr	Thr	Asp	Trp	Val	Asp	Asp	Gln	Arg	Pro	Glu	Asn
	370					375					380				
Tyr	Arg	Glu	Ala	Leu	Gly	Asp	Val	Val	Gly	Asp	Tyr	Asn	Phe	Ile	Cys
	385					390					395				400
Pro	Ala	Leu	Glu	Phe	Thr	Lys	Lys	Phe	Ser	Glu	Trp	Gly	Asn	Asn	Ala
				405					410					415	
Phe	Phe	Tyr	Tyr	Phe	Glu	His	Arg	Ser	Ser	Lys	Leu	Pro	Trp	Pro	Glu
			420						425					430	
Trp	Met	Gly	Val	Met	His	Gly	Tyr	Asp	Ile	Glu	Phe	Val	Phe	Gly	Leu
		435					440					445			
Pro	Leu	Glu	Arg	Arg	Asp	Asn	Tyr	Thr	Lys	Ala	Glu	Glu	Ile	Leu	Ser
	450					455					460				
Arg	Ser	Ile	Val	Lys	Arg	Trp	Ala	Asn	Phe	Ala	Lys	Tyr	Gly	Asn	Pro
	465					470					475				480
Asn	Glu	Thr	Gln	Asn	Asn	Ser	Thr	Ser	Trp	Pro	Val	Phe	Lys	Ser	Thr
				485					490					495	
Glu	Gln	Lys	Tyr	Leu	Thr	Leu	Asn	Thr	Glu	Ser	Thr	Arg	Ile	Met	Thr
			500						505					510	
Lys	Leu	Arg	Ala	Gln	Gln	Cys	Arg	Phe	Trp	Thr	Ser	Phe	Phe	Pro	Lys
		515					520						525		

-continued

Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys  
530 535 540

Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln  
545 550 555 560

Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu  
565 570

<210> SEQ ID NO 27

<211> LENGTH: 1125

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)  
BChE nucleic acid sequence for amino acid residues 68-442

<400> SEQUENCE: 27

```

aacatagatc aaagttttcc aggcctccat ggatcagaga tgtggaaccc aaacactgac    60
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc    120
actgtattga tatggattta tgggtgggtg tttcaaaactg gaacatcatc tttacatggt    180
tatgatggca agtttctggc tcgggttgaa agagtattg tagtgtcaat gaactatagg    240
gtgggtgccc taggattcct agccttgcca ggaaatcctg aggcctccagg gaacatgggt    300
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga    360
aatcctaaaa gtgtaactct ctttgagaaa agttccggag cagcttcagt tagcctgcat    420
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct    480
aatgctcctt gggcggaac atctctttat gaagctagga acagaacggt gaacttagct    540
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa    600
gatccccaag aaattcttct gaatgaagca tttgtgttcc cctatgggac tcctttgggt    660
gtaaactttg gtccgaccgt ggatggatgat tttctcactg acatgccaga catattactt    720
gaacttggac aatttaaaaa aaccagatt ttggtgggtg ttaataaaga tgaagggaca    780
tggtttttag tctatggtgc tcttggtctc agcaaagata acaatagtat cataactaga    840
aaagaatttc aggaagggtt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa    900
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag    960
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttggg gttcaccaag   1020
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa   1080
cttccgtggc cagaatggat gggagtgatg catggctatg acatt                          1125

```

<210> SEQ ID NO 28

<211> LENGTH: 375

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)  
BChE amino acid sequence for residues 68-442

<400> SEQUENCE: 28

Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn  
1 5 10 15

Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile  
20 25 30

Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly  
35 40 45

-continued

Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys  
 50 55 60  
 Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg  
 65 70 75 80  
 Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro  
 85 90 95  
 Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln  
 100 105 110  
 Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe  
 115 120 125  
 Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro  
 130 135 140  
 Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala  
 145 150 155 160  
 Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr  
 165 170 175  
 Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu  
 180 185 190  
 Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn  
 195 200 205  
 Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly  
 210 215 220  
 Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu  
 225 230 235 240  
 Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys  
 245 250 255  
 Asp Glu Gly Thr Trp Phe Leu Val Tyr Gly Ala Pro Gly Phe Ser Lys  
 260 265 270  
 Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys  
 275 280 285  
 Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe  
 290 295 300  
 His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu  
 305 310 315 320  
 Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu  
 325 330 335  
 Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr  
 340 345 350  
 Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly  
 355 360 365  
 Val Met His Gly Tyr Asp Ile  
 370 375

&lt;210&gt; SEQ ID NO 29

&lt;211&gt; LENGTH: 975

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)  
 BChE nucleic acid sequence for amino acid residues 117-441

&lt;400&gt; SEQUENCE: 29

gggtttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60  
 gaaagagtta ttgtagtgtc aatgaactat aggggtgggtg ccctaggatt cttagctttg 120  
 ccaggaatc ctgaggctcc agggaacatg gggtttattg atcaacagtt ggctcttcag 180

-continued

---

```

tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240
gaaagttccg gagcagcttc agttagcctg catttgcttt ctctggaag ccattcattg 300
ttcaccagag ccattctgca aagtggttcc gctaagtctc cttgggcggg aacatctctt 360
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420
gagactgaaa taatcaagtg tcttagaagt aaagatcccc aagaattct tctgaatgaa 480
gcatttggtg tcccctatgg gactcctttg ggtgtaaact ttggtccgac cgtggatggt 540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaaccag 600
attttggtgg gtgtaataa agatgaaggg acatggtttt tagtctatgg tgctcctggc 660
ttcagcaaag ataacaatag taccataact agaaaagaat ttcaggaagg tttaaaaata 720
tttttccag gagtgagtga gtttgaaaag gaatccatcc ttttctatta cacagactgg 780
gtagatgac agagactga aaactaccgt gaggccttg gtgatgtgt tggggattat 840
aatttcata gcctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900
ttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960
atgcatggct atgac 975

```

```

<210> SEQ ID NO 30
<211> LENGTH: 325
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)
      BChE amino acid sequence for residues 117-441

```

```

<400> SEQUENCE: 30

```

```

Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe
1           5           10           15
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val
20          25          30
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly
35          40          45
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys
50          55          60
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly
65          70          75          80
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly
85          90          95
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn
100         105         110
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu
115         120         125
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile
130         135         140
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu
145         150         155         160
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro
165         170         175
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu
180         185         190
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp
195         200         205

```

-continued

---

Glu	Gly	Thr	Trp	Phe	Leu	Val	Tyr	Gly	Ala	Pro	Gly	Phe	Ser	Lys	Asp
210						215					220				
Asn	Asn	Ser	Ile	Ile	Thr	Arg	Lys	Glu	Phe	Gln	Glu	Gly	Leu	Lys	Ile
225					230					235					240
Phe	Phe	Pro	Gly	Val	Ser	Glu	Phe	Gly	Lys	Glu	Ser	Ile	Leu	Phe	His
				245					250					255	
Tyr	Thr	Asp	Trp	Val	Asp	Asp	Gln	Arg	Pro	Glu	Asn	Tyr	Arg	Glu	Ala
			260					265						270	
Leu	Gly	Asp	Val	Val	Gly	Asp	Tyr	Asn	Phe	Ile	Cys	Pro	Ala	Leu	Glu
		275					280					285			
Phe	Thr	Lys	Lys	Phe	Ser	Glu	Trp	Gly	Asn	Asn	Ala	Phe	Phe	Tyr	Tyr
		290				295					300				
Phe	Glu	His	Arg	Ser	Ser	Lys	Leu	Pro	Trp	Pro	Glu	Trp	Met	Gly	Val
305					310					315					320
Met	His	Gly	Tyr	Asp											
				325											

---

The invention claimed is:

1. A butyrylcholinesterase variant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 8, 14, and 26.

2. A pharmaceutical composition comprising:

a butyrylcholinesterase variant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 8, 14, and 26; and a suitable pharmaceutical carrier.

3. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of

25 a butyrylcholinesterase variant polypeptide of claim 1 to lower blood cocaine concentration.

4. The method of claim 3, wherein said butyrylcholinesterase variant polypeptide exhibits a one-hundred-fold or more increase in cocaine hydrolysis catalytic efficiency compared to butyrylcholinesterase.

30 5. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of a BChE butyrylcholinesterase pharmaceutical composition of claim 2 to lower blood cocaine concentration.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,731,957 B1  
APPLICATION NO. : 12/192394  
DATED : June 8, 2010  
INVENTOR(S) : Zhan et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 99, line 25-27 should read

What is claimed is:

1. A butyrylcholinesterase variant peptide comprising the amino acid sequence of SEQ ID NO 14.

Column 99 lines 28-33 should read

2. A pharmaceutical composition comprising:  
a butyrylcholinesterase variant peptide comprising the amino acid sequence of SEQ ID NO 14 and a suitable pharmaceutical carrier.

Column 99 lines 34-35 - Column 100 lines 1-2 should read

3. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of the butyrylcholinesterase variant polypeptide of claim 1 to lowering blood cocaine concentration.


Column 100 lines 3-4 should read

4. The method of claim 3, wherein said butyrylcholinesterase variant polypeptide exhibits a one-hundred-fold or more increase in cocaine hydrolysis catalytic efficiency compared to wild-type butyrylcholinesterase.

Column 100 lines 5-8 should read

5. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of the BChE butyrylcholinesterase pharmaceutical composition of claim 2 to lower blood cocaine concentration.

Signed and Sealed this  
Fourth Day of January, 2011



David J. Kappos  
*Director of the United States Patent and Trademark Office*